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ABSTRACT 
 
 
 BACKGROUND: Tumor cell proliferation, invasion and metastasis are known to 
be mediated, at least in part, through degradation of basement membrane by neutral 
metalloproteinases (MMP) produced by tumor and stromal cells. MMP-9 is known to 
play a significant role in breast tumor cell invasion and metastasis via degradation of 
ECM components and activation of cytokines and chemokines.  MMP-9 is known to 
cleave type IV collagen, one of the most abundant collagens of the extracellular matrix. 
Our lab has found that the fully processed (68 kDa) form of MMP-9 generated in tumor 
and stromal cells is also capable of cleaving type I collagen molecule with similar 
characteristics of MMP-1.  This observation raises questions regarding the significance of 
each MMP in tumor cell invasion and metastases. Thus, in combating tumor growth and 
invasion, understanding the mechanism of substrate specificity and design of a novel 
therapeutic compound that is capable of specifically down regulating MMP-9 expression 
are of interest.  
 
 METHOD: DNAzymes are catalytic oligonucleotides that bind to and cleave 
specific mRNA, resulting in a decreased protein expression.  The safety and efficacy of 
anti-MMP-9 DNAzyme (AM9D) in vivo was determined by injecting 
35
S-labeled AM9D 
(
35
S-AM9D) into the tail vein of healthy and MMTV-PyMT transgenic mice and the 
amount of 
35
S-AM9D accumulated in different tissues was measured as a function of 
time. The effect of AM9D treatment on breast tumor progression was tested by four 
once-weekly intratumoral injections of two concentrations of AM9D into mammary 
tumors of MMTV-PyMT transgenic mice at early stages of tumor development. The 
tumor sizes were measured at the end of the experiments.  The effect of AM9D treatment 
on early stage experimental metastasis and survival was evaluated by injecting FVB 
female mice with 1x10
6 
luciferase labeled mammary tumor epithelial cells (luc-MTEC) 
isolated from MMTV-PyMT mice and treating the animals with AM9D, control 
DNAzyme, or PBS for 3 weeks or up to 10 weeks, respectively. 
  
The mechanism of substrate specificity of 68 kDa MMP-9 was determined by 
generating a series of truncated and site directed mutant forms of MMP-9.  Specific 
amino acid residue in sequence 
444
PRPEPEPRPPTTT
456 
in the hinge region responsible 
for substrate selectivity of the enzyme was then identified by alanine-scanning site 
directed mutagenesis. The charged amino acid residues (Arg
445
, Glu
447
, Glu
449
, and 
Arg
451
) were individually replaced by Ala and the proteolytic activity of the mutant 
enzymes toward Mca-PLGL(Dpa)AR-NH2, gelatin, and type I collagen was determined. 
 
 RESULTS: Treatment of MDA-MB-231 breast cancer cell line with AM9D in 
vitro resulted in decreased invasion potential of the cells and intratumoral treatment of 
MMTV-PyMT mice in vivo resulted in delayed rate of tumor growth and retarded final 
tumor volume by up to 51%. This decrease in tumor growth was correlated with 
decreased MMP-9 protein production within the treated tumor tissues. Tumors treated 
with AM9D were also less vascular compared to control and untreated tumors. 
Furthermore, DNAzyme administered IV is distributed to major organs including lung, 
vi 
without showing any organ toxicity. Intravenous administration of AM9D and control 
DNAzyme in animals bearing luc-MTECs were able to decrease the number of gross 
lung macro metastasis. In addition, AM9D treatment increased progression-free survival 
but did not have an effect on overall survival of animals inoculated with luc-MTECs 
compared to control DNAzyme and PBS treatment. These data indicate that AM9D can 
be used individually or as an adjuvant to current chemotherapy for breast cancer. 
 
 To further illuminate the role of MMP-9 in tumor growth and metastases the 
mechanism of substrate specificity of the enzyme was studied. Site directed and deletion 
mutagenesis revealed that interaction of Glu
415 
in the active site with Glu
447
 and/or Arg
451
 
in the hinge region makes the active site rigid, preventing full length MMP-9 from 
cleaving type I collagen. Disruption of this interaction, on the other hand, provides the 
flexibility necessary for the enzyme’s active site to change conformation and be able to 
bind and cleave type I collagen substrate.  
 
 CONCLUSION: Given that MMP-9 is capable of cleaving type I collagen and its 
down regulation hinders the development of breast cancer in an animal model, AM9D 
could prove useful as an adjuvant therapy against breast carcinoma cell invasion. 
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CHAPTER 1.    INTRODUCTION 
 
 
BACKGROUND 
 
 
Breast Cancer  
 
 Breast cancer is one of the leading causes of cancer deaths in women, second only 
to lung cancer [1]. Breast cancer is divided into three subtypes based on the tumor cells 
expression of estrogen receptor (ER), progesterone receptor (PR), and/or HER2. The 
aforementioned subtypes of breast cancer are known as luminal A (ER or PR
+
/HER2
-
), 
luminal B (ER or PR
+
/HER2
+
), and triple negative (ER
-
/PR
-
/HER2
-
) [2]. The American 
Cancer Society estimated that in 2010 there would be 207,090 new cases of invasive and 
57,010 new cases of non-invasive breast cancer diagnosed in women. In 2010, about 
39,840 women were expected to die as a result of breast cancer. The spread of cancer 
cells to distant organs, metastasis, is responsible for the majority of morbidity and 
mortality [3-5]. In the case of breast cancer, metastasis affects the lungs, regional lymph 
nodes and bone, while less frequently affecting brain and liver [6]. This metastasis and 
eventual tumor growth at distant sites depends on interaction between tumor cells, 
stromal cells, and the host microenvironment [7]. Since the main event separating those 
that survive breast cancer and those who fall victim to breast cancer is metastasis, it is as 
important to develop therapeutic strategies against the metastatic process as for any other 
process in the breast cancer spectrum.  
 
 It has been widely hypothesized that metastasis occurs when cells from the 
primary tumor undergo sequential steps to make them more adaptable to seed tumors in 
distant organs. These sequential steps include the transition of epithelial cells to 
mesenchymal like cells (epithelial to mesenchymal transition; EMT), degradation of the 
extracellular membrane (ECM), intravasation, extravasation, and finally transition back 
to epithelial like cells (mesenchymal to epithelial transition; MET) [8]. This transition has 
been shown to involve matrix metalloproteinases (MMP) produced by tumor and stromal 
cells [9]. These enzymes enable the invasion of carcinoma cells into adjacent normal 
tissue by degrading the extracellular (ECM) and basement membrane components. 
 
 
Matrix Metalloproteinases (MMP) 
 
 MMPs are a family of over 24 proteolytic enzymes and essential regulators of 
cells microenvironment [10]. These enzymes are secreted as catalytically latent species, 
which are processed to their activated forms in vivo by other proteinases [11]. Most 
human MMPs are categorized into five main subclasses based on their substrate 
specificity, collagenases (MMP1, MMP8, and MMP13), stromelysin (MMP3, MMP10, 
MMP11, MMP7 and MMP26), gelatinases (MMP2 and MMP9), membrane type MMPs 
(MMP14, MMP15, MMP16, MMP17, MMP24, and MMP25) [10, 11] and 
metalloelastase (MMP-12) [12]. MMPs cleave virtually all components of the ECM and 
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overlap in their substrate specificity. Collagenases can cleave native fibrillar collagen 
types I, II, and III [13]. Although less well studied, the collagenases can also cleave 
collagen types VII and X as well as gelatin, aggrecan, entactin, and tenascin [14]. 
Stromylysins digest native collagen types III, IV, V, IX, X, and XI, as well as, tenascin, 
gelatin, aggrecan, and many other substrates [14]. Gelatinases digest elastin, aggrecan, 
and collagen types IV, V, and XI [14]. They also act synergistically with interstitial 
collagenase in the degradation of fibrillar collagens. Recent studies have shown that 
MMP-2 can cleave native type I collagen in the same position as MMP-1 [15], and 
MMP-9 cleaves ?2 chains of type I collagen [16]. Finally, a few of the MT-MMP 
substrates are collagens type I, II, and III, gelatin, casein, fibronectin, laminin, 
vitronectin, and entactin [14]. 
 
 As evidenced by their substrate specificity, MMPs play a significant role in 
normal and pathological conditions that involve matrix degradation and remodeling [17]. 
This includes, but is not limited to, wound healing, post partum involution, congestive 
heart failure, rheumatoid arthritis, osteoarthritis, and cancer (reviewed in [18-22]). In 
cancer, degradation of the ECM by MMPs not only enhances tumor invasion, but also 
affects tumor cell behavior and leads to cancer progression [10]. 
  
 Metastasis, a multi step process, involves dissemination of cells from the primary 
tumor to distant organs or tissues and the formation of secondary tumors. Expression of 
MMPs apparently leads to dissociation of cell-cell and cell-ECM adhesion through the 
processing of cadherins, thereby leading to EMT initiation [8, 23, 24]. This transition can 
lead to increased extracellular proteolytic activity further promoting migration. MMPs 
are also capable of affecting cell regulatory signaling, directly or indirectly, within the 
extracellular microenvironment, which ultimately affects the cells intracellular signaling 
[25]. This is achieved by their role in the bioavailability of multiple growth factors and 
cytokines [10, 25].  MMPs also cleave insulin-like growth factors and release 
transmembrane precursors of growth factors, including TGF-?, which aids in 
proliferation [10]. Thus, MMPs are important through their ability to affect tumor 
initiation and growth via cell adhesion independency, evasion of apoptosis, disruption of 
proper cell division, and as mediators of metastasis during late stage malignancy [25].  
 
 
MMP-9 in Cancer 
 
 It has been suggested that the production of MMPs in general and MMP-9 in 
particular is one of the most important factors for migration of tumor cells into the 
bloodstream or lymphatic vessels, or into adjacent normal tissues [26, 27]. MMP-9 
(gelatinase B) has been shown to be closely associated with invasion and metastasis [28, 
29]. MMP-9 degrades type IV collagen, one of the most abundant collagens in the ECM 
[22], and is involved in angiogenesis and proliferation. With the use of multistage 
pancreatic carcinogenesis in a transgenic RIP1-Tag2 mouse model, MMP-9 was shown to 
be up-regulated in angiogenic islets, leading to an increase in the bioavailability of VEGF 
[30]. Xu, et al. evidenced that MMP-9’s cleavage of type IV collagen exposes an 
otherwise hidden HUIV26 cryptic site which is important in angiogenesis and tumor 
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growth in vivo [31]. Rao, et al. have demonstrated the down regulation of MMP-9 
increased ?1-integrin which leads to ERK activation and apoptosis through one of two 
mechanisms: (1) release of cytochrome C into the cytosol and/or (2) increase in NF-kB 
activation, which both lead to subsequent activation of caspase 3 [32].  Although few cell 
types express MMP-9 constitutively, the majority of human metastatic tumor cells (i.e. 
melanoma, fibrosarcoma, breast adenocarcinoma, glioma, etc.) that have been tested 
consistently show elevated MMP-9 activity compared with benign control cells [33-36]. 
In addition, tumor cells stably expressing the MMP-9 cDNA have been shown to 
metastasize in nude mice [37]. Furthermore, inhibition of MMP-9 activity has been 
demonstrated to block the invasive behavior of breast carcinoma cells, MDA-MB-231 
[38].  Thus, inhibition of MMP-9 expression can be used as a therapeutic modality to 
decrease growth and invasion of tumor cells.  
 
  Analyses of the primary structures of MMPs revealed that these proteins could be 
divided into several distinct domains with apparent specific functions (Figure 1-1). A 
typical secreted MMP has three major domains: NH2-terminal prodomain, central 
catalytic domain, and COOH-terminal hemopexin-like domain [18, 27]. The 
characterization of MMP-9 revealed two additional domains, one with homology to the 
gelatin-binding region of fibronectin and the other with a collagen-like sequence [39]. 
The fibronectin-like gelatin binding domain has been shown to be important for the 
gelatinolytic and type V collagenolytic activity of the enzyme [40].   Structural 
similarities among MMP members have made it very difficult to develop specific 
synthetic inhibitor for MMP-9 as a potential cancer therapeutic agent. The lack of 
specificity of most active site directed MMP inhibitors that entered clinical trials made  
 
 
 
 
 
Figure 1-1. Structural domains of matrix metalloproteinases.  
 
This is a schematic diagram showing the main structural domains of Collagenases 
(MMP-1) and Gelatinases (Gelatinase B, MMP-9; Gelatinase A, MMP-2). Gelatinases 
contain two additional domains compared to collagenases, the gelatin-binding domain 
and the collagen-like domain. 
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them more harmful than helpful [41].  For example, Batimastat, the first synthetic MMP 
inhibitor studied in humans, showed reduced growth of primary tumor, onset of distant 
metastases, and even prolonged survival of animals with pancreatic, orthotopic colon, or 
orthotopic liver tumor [42-44]. In addition, Marimastat, a derivative of Batimastat 
significantly increased progression-free survival in the patients with inoperable gastric 
cancer, without improving overall survival [45]. Despite favorable results of these 
synthetic MMP inhibitors in animal systems and human clinical trials, they lead to 
significant side effects, which include but are not limited to fatigue, anorexia, nausea, 
vomiting, asthenia, and inflammatory polyarthritis [46, 47]. These multiple side effects 
associated with usage of the non-specific MMP inhibitors in clinical trials are 
comprehensible since as stated above, MMPs are required for normal physiological 
processes such as cell growth and remodeling, ovulation, and wound healing. In addition, 
two MMP members, MMP-3 and -8, have been identified as cancer anti-targets because 
their down regulation results in initiation of the disease or deleterious alteration in disease 
progression [27]. In order to over come this problem, the mechanism of substrate 
specificity of MMP-9 must be identified and considered in the design of the specific 
inhibitor to be used for cancer therapy.  
 
 The role of the hemopexin-like carboxyl terminal domain of MMP-9 is of interest, 
since we have recently shown that it dictates substrate specificity of the enzyme (please 
see below). The role and significance of collagen-like and hemopexin-like carboxyl 
terminal domains in substrate specificity of MMP-9 has been investigated in Chapter 5. 
 
 
DNAzymes as Novel Treatments for Cancer 
 
Over the past few years, DNAzymes have been used in vitro to selectively inhibit 
or modify specific mRNA levels in mammalian cell cultures [48]. DNAzymes are 
catalytic DNA molecules that in the absence of proteins bind to and cleave specific 
mRNA sequences, which results in the decreased expression of the encoded protein [49] 
(Figure 1-2).  
 
 DNAzymes have emerged as novel, highly selective inhibitors or modulators of 
gene expression [50]. Khachigian and colleagues have reported that the DNAzymes 
targeting early growth response factor-1 (Egr-1) mRNA inhibits neointimal formation 
after balloon injury to the rat carotid artery wall and reduce intimal thickening after 
stenting pig coronary arteries. DNAzyme targeting c-Jun caused repair of injured rat 
carotid arteries [51].  Upregulation of Aurora kinase A has been shown to be important in 
carcinogenesis of prostate cancer. DZ2, an Aurora kinase A specific DNAzyme was 
shown to strongly inhibit Aurora kinase A in a prostate cancer cell line in vitro and 
inhibit tumor growth of human prostate cancer xenografts in nude mice [52]. Finally, a 
DNAzyme targeting vascular endothelial growth factor receptor 2 (VEGFR2) 
significantly inhibited the growth of breast tumors derived from xenografting 
MDA-MB-435 cells into nude mice by inducing apoptosis [53]. These data demonstrate 
that these small nucleotide mRNA cleaving sequences can potentially be designed and 
administered to target specific genes with relative lack of toxicity. DNAzymes have  
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Figure 1-2. Composition of the 10-23 catalytic motifs.  
 
The DNA enzyme (bottom strand) binds the RNA substrate (top strand) through 
Watson-Crick pairing. Cleavage occurs at the position indicated by the arrow. R=Purine 
(A or G); Y=Pyrimidine (U or C). Reprinted with permission from Santoro SW, Joyce 
GF (1997). A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 
94: 4262-4266. 
 
 
excellent potential as a biotherapy against matrix metalloproteinases.  
 
 As stated above, since DNAzyme molecules can be designed to target a specific 
gene with relative lack of toxicity, it is expected that specific down regulation of MMP-9 
by DNAzyme will prevent tumor cell invasion and metastasis while generating a 
minimum side effect.  
 
 
Design and In Vitro Efficacy of Anti-MMP-9 DNAzyme (AM9D)  
 
 To test whether down regulation of MMP-9 by an MMP-9 mRNA targeted 
DNAzyme could be used as a treatment strategy for cancer, Dr. Hasegawa, a postdoctoral 
fellow in our laboratory, designed several anti-MMP-9 DNAzymes (AM9D) according to 
putative DNAzyme target sites in the predicted secondary structure of MMP-9 mRNA 
and selected the most efficient AM9D with respect to its activity toward RNA substrate. 
As shown in Figure 1-3a, only AM9D-2 (lane 3) and AM9D-5 (lane 6) were able to 
efficiently cleave over 85% of the RNA substrate in 2 h at 37 ˚C as determined by the 
density of the RNA fragment products. These reactions were time dependent as a longer 
incubation of the RNA substrate with the AM9D-2 and AM9D-5 led to complete 
cleavage of the RNA molecule (data not shown).  The AM9D-1, scrambled control, and 
sense control DNAzymes (lanes 2, 7 and 8, respectively) at the same concentration did 
not have any activity toward the RNA substrate. AM9D-3 and -4 (lanes 4 and 5) were 
able to cleave only ~ 25% of the RNA substrate. AM9D-5 (referred to in this body of 
work as AM9D) and scrambled control DNAzyme was used for further studies.  
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Figure 1-3. Efficacy of anti-MMP-9 DNAzyme (AM9D) in vitro.  
 
(a) Urea-Polyacrylamide gel electrophoresis of cleaved MMP-9-RNA by DNAzyme. 
Anti MMP-9 DNAzymes, scrambled, or sense control DNAzymes (12.5 μM) were 
incubated with MMP-9 RNA substrate (764 nt, 0.48 μM) for 2 h at 37 ˚C and the 
products were analyzed by polyacrylamide-urea gel.  Lane 1, RNA substrate alone;     
lane 2, AM9D-1; lane 3, AM9D-2; lane 4, AM9D-3; lane 5, AM9D-4; lane 6, AM9D-5; 
lane 7, Scrambled control; and lane 8, Sense control DNAzymes. The RNA bands were 
visualized by Ethidium Bromide staining. The lowest molecular weight bands are 
DNAzyme.   (b) AM9D reduced MMP-9 mRNA level. MMP-9 stably transfected COS-7 
cells (COS-7 NG) were transfected with Oregon Green 488 labeled DNAzymes. 
Positively transfected cells were identified by flow cytometry. Total RNA was isolated 
and MMP-9, MMP-2, and ß-actin mRNA were amplified by RTPCR. The PCR products 
were subjected to agarose gel and visualized by Ethidium Bromide staining. Lane 1, 
AM9D-5; lane 2, control DNAzyme; lane 3, Cells treated with DOTAP transfection 
reagent only and lane 4, the PCR product from parental COS-7 cells (non-transfected 
with MMP-9). (c) AM9D decreased MMP-9 production. Culture media from MMP-9 
stably transfected COS-7 cells (COS-7 NG) treated with DOTAP alone (lane 1), control 
DNAzyme (lane 2), and AM9D-5 (lane 3) were separated on gelatin zymogram gel. As 
shown, AM9D-5 down regulates production of MMP-9 in COS-7 NG cells. (d) AM9D 
decreased the invasive behavior of human MDA-MB-231 breast cancer cells. The 
percentage ratio of carcinoma cells invading the Matrigel Matrix after treatment with 
AM9D-5 against that of cells treated with control DNAzyme after 24 h. The AM9D-5 
transfected cells showed a 43% reduction in cell invasion compared to control DNAzyme 
transfected cells. 
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 To assess the effect of AM9D-5 on MMP-9 production in vitro, monkey kidney 
cells lacking MMP-9 (COS-7 cells, Figure 1-3b, lane 4) were stably transfected with 
MMP-9 cDNA to constitutively express the protein. The effect of AM9D-5 on the 
production of MMP-9 in the stably transfected cells (COS-7 NG) was then examined by 
transiently transfecting the cells with different amounts of either control DNAzyme or 
AM9D-5 using Gene PORTER (Genlantis, San Diego, CA).  Twenty-four h after 
transfection, the cells were harvested, total RNA was extracted, and condition media 
were examined for the presence of MMP-9 mRNA and protein by RT-PCR (Figure 1-3b) 
and by gelatin gel zymography (Figure 1-3c), respectively.  As demonstrated in Figure 
1-3b and c, AM9D-5 was able to significantly reduce the level of the MMP-9 mRNA 
(Figure 1-3b, lane 1) and protein as evidenced by the low enzyme activity in AM9D-5 
treated COS-7 NG cells (Figure 1-3c, lane 3) compared to non-treated and control 
DNAzyme treated cells (Figure 1-3c, lanes 1 and 2, respectively).  
 
 To demonstrate the specificity of AM9D toward MMP-9 mRNA its activity 
toward MMP-2 mRNA, a closely related enzyme to MMP-9, was determined.  COS-7 
cells constitutively express MMP-2 (Figure 1-3b and c).  Stably transfecting COS-7 cells 
with MMP-9 cDNA (COS-7 NG) and treating the cells with AM9D-5 did not have any 
effect on MMP-2 mRNA (Figure 1-3b) or protein (Figure 1-3c) expression levels.  This 
data clearly demonstrates that the AM9D-5 is very specific and it only affects the MMP-9 
production in cells. 
 
 To determine the effect of decreased MMP-9 mRNA expression on the invasive 
behavior of cancer cells, MDA-MB-231 highly invasive breast cancer cells were 
transiently transfected with fluorescently labeled AM9D-5 or control DNAzyme, FACS 
sorted and the invasive behavior of the sorted cells was determined using ECMatrix™ 
(Millipore, Billerica, MA) invasion chamber. The mean invasion potential of 
MDA-MB-231 cells decreased by 43% when transfected with AM9D-5 compared to 
control DNAzyme treated cells (Figure 1-3d). These data indicate that MMP-9 
significantly contributes to the invasive behavior of MDA-MB-231 tumor cells and 
provides evidence that AM9D treatment significantly and specifically reduces MMP-9 
production and suppresses the invasive behavior of breast tumor cells in vitro. Thus, 
AM9D may be a useful anti-tumorigenic and anti-metastatic agent in vivo.  
 
 
RESEARCH OBJECTIVES AND SPECIFIC AIMS  
 
 
Objective 
 
The objective of this proposal was to evaluate the efficacy of an MMP-9 targeted 
DNAzyme as a therapy in treating breast carcinoma and preventing lung metastasis. If 
anti-MMP-9 DNAzyme (AM9D) therapy is proven useful in reducing tumor growth and 
preventing metastasis in an animal model of breast cancer, this will be an important step 
in the preclinical development of a new biotherapy with excellent potential for expanding 
the standard of care for breast cancer patients. 
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Specific Aim 1 
 
 The first aim of this body of work was to test the efficacy of anti-MMP-9 
DNAzyme oligonucleotides on tumor growth in MMTV-PyMT transgenic mice. This 
was accomplished by intratumorally injecting control DNAzyme or AM9D into 
mammary tumors once a week, for 4 weeks, at an early palpable tumor size. Tumor sizes 
were measured weekly and the animals were sacrificed at a selected time point (one week 
after the 4
th
 injection). The efficacy of MMP-9 downregulation by AM9D on the rate of 
tumor growth, final tumor load, development of new vasculature, and tumor cell survival 
was evaluated.  
 
 
Specific Aim 2  
 
 The second aim of this body of work was to determine the distribution, clearance, 
and cytotoxicity of AM9D.  This was accomplished by intravenously injecting              
35
S-labeled DNAzyme ([
35
S]-DNAzyme) molecule into normal and tumor-bearing 
MMTV-PyMT mice, sacrificing mice at various time points (2 h -7 days), and 
determining the amount of DNAzyme in organs and mammary tumors. To determine 
organ toxicity by DNAzyme in general and the anti-MMP-9 DNAzyme (AM9D) in 
particular, mice were injected with PBS or escalating concentrations (200 ?g, 650 ?g, or 
1500 ?g) of AM9D or control DNAzyme. Mice were sacrificed on day 7 post treatment 
and a Pathologist evaluated major organs for any signs of toxicity. 
 
 
Specific Aim 3 
 
 The third aim of this body of work was to determine the effect of AM9D on 
experimental metastasis. To accomplish this goal normal FVB mice were injected with 
luciferase labeled mammary tumor epithelial cells (luc-MTEC) derived from the 
MMTV-PyMT transgenic mice used in the experiments described in specific aim 1. Mice 
received weekly intravenous injections of AM9D, control DNAzyme, or PBS.  These 
mice were sacrificed on day 21 or when they displayed signs of lethargy due to lung 
tumor burden to assess the role of AM9D on early stage experimental metastasis and 
overall survival, respectively.   
 
 
Specific Aim 4  
 
 The fourth aim of this body of work was to determine the mechanism of substrate 
specificity of MMP-9.  As stated above, degradation of basement member components by 
MMP is one of the first steps in tumor cell invasion and metastasis. Our data indicate that 
contrary to a general belief that MMP-9 only cleaves types IV and V and XI collagen, 
MMP-9 generated by tumor and stroma cells is also capable of cleaving type I collagen. 
Thus, understanding the mechanism behind collagen substrate specificity of MMP-9 
sheds light on its role in metastasis, the major cancer-surviving determinant. Specific 
9 
domain(s) and amino acid residues responsible for substrate specificity of the enzyme 
were identified by deletion and Ala scanning site directed mutagenesis of the MMP-9 
molecule. 
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CHAPTER 2.    TREATMENT OF TUMOR GROWTH WITH AM9D 
 
 
INTRODUCTION 
 
 Accumulating evidence suggests that production of matrix metalloproteinase-9 
(MMP-9) by tumor and stroma cells is one of the most important factors for metastatic 
behavior of tumor cells [8, 23, 54]. MMP-9 is a member of the matrix metalloproteinase 
family of enzymes, which play an important role in normal physiological responses, 
including wound healing and bone formation [55]. Some MMPs, including MMP-9, 
become deregulated during tumorigenesis and are associated with pro-oncogenic events 
such as neo-angiogenesis, tumor cell proliferation and metastasis [9]. For example, 
MMP-9 was shown to be upregulated in angiogenic islets of the RIP-Tag2 transgenic 
mouse model of pancreatic cancer, leading to an increase in the distribution of VEGF, a 
potent pro-angiogenic factor [30]. Moreover, high levels of MMP-9 expression in breast 
cancers have been shown to be positively correlated with enhanced tumor cell invasion 
and metastasis [28, 29] and with enhanced progression and poor prognosis [9].  
 
  MMP-9 is conserved across several species (human, chimpanzee, dog, cow, 
mouse, rat, chicken, zebrafish, and A.thaliana). MMP-9 degrades type IV collagen, one 
of the most abundant collagens in the extracellular matrix (ECM) [56], which may 
stimulate local invasion, the first step in metastasis.  In addition, MMP-9 also cleaves 
pro-cytokines, chemokines, and growth factors, thereby modifying their biological 
activity [10, 25, 57]. In addition, tumor cells that stably express MMP-9 cDNA have been 
shown to have enhanced metastastic ability [37]. Thus, inhibition of MMP-9 expression 
by our Anti-MMP-9 DNAzymes could be a useful therapeutic modality to decrease the 
growth and invasive properties of tumor cells.  
  
 As described previously, DNAzymes have been used by several investigators to 
selectively inhibit or modulate different gene expressions in vivo [50]. Khachigian and 
colleagues have reported that the DNAzymes targeting early growth response factor-1 
(Egr-1) mRNA inhibits neointimal formation after balloon injury to the rat carotid artery 
wall and reduce intimal thickening after stenting pig coronary arteries. DNAzyme 
targeting c-Jun caused repair of injured rat carotid arteries [51].  Finally, a DNAzyme 
targeting vascular endothelial growth factor receptor 2 (VEGFR2) significantly inhibited 
the growth of breast tumors derived from xenografting MDA-MB-435 cells into nude 
mice [53]. 
 
The purpose of the present study was to evaluate the effect of AM9D on breast 
tumor growth in the MMTV-PyMT mouse model of breast cancer.  It is demonstrated for 
the first time that once weekly intratumoral injection of AM9D, in the absence of any 
carrier molecule, for four weeks was sufficient to significantly reduce the rate of tumor 
growth and final tumor load in a dose dependent and statistically significant manner       
(p?0.05). Together, the data presented here justify the further development of AM9D for 
its potential as an anti-tumor agent and as an ideal candidate for breast cancer therapy.  
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MATERIALS AND METHODS 
 
 
DNAzyme 
 
 All DNA oligonucleotides used in these experiments were synthesised by 
Integrated DNA Technology (Coralville, IA). The sequence of the DNAzyme targeting 
mRNA of human and mouse MMP-9 is, 5'-GTGGTGCCAGGCTAGCTACAACGA 
TTGAGGCG-3’.  In the control DNAzyme, 5'-CTAGTCAGCGGCTAGCTACAACG 
ATAAGCTGCT-3', the catalytic sequence of DNAzyme is flanked by 9 bases randomly 
chosen and not specific for any MMP coding sequence. DNAzyme used in some of the 
experiments was labeled with Oregon Green? 488 C5-maleimide  (Invitrogen, Carlsbad, 
CA). Oregon Green? 488 C5-maleimide was prepared in dimethyl sulfoxide to a stock 
concentration of 25mM. The 5?-hydroxyl terminus of the DNAzyme was labeled initially 
with ATP?S (Sigma, St. Louis, MO; 600 ?M) using T4 Polynucleotide kinase (New 
England Biolabs, Ipswich, MA; 30U) followed by Oregon Green 488 maleimide (1mM) 
at 37°C as suggested by manufacture. The labeled DNAzyme was then purified by 
ethanol precipitation.  
 
 
MMTV-PyMT Transgenic Mammary Tumor Model 
 
The MMTV-PyMT transgenic mice express polyoma middle T antigen under the 
control of mouse mammary tumor virus long terminal repeat [58]. The MMTV-PyMT 
transgenic mouse model is a widely used preclinical model of estrogen and progesterone 
receptor negative luminal breast cancer with well-defined stages of progression and 
metastasis to lung [59, 60]. On a pure FVB/Nj strain background, all PyMT-positive 
females exhibit an average tumor latency of 58 days after birth, independent of pregnancy 
and will eventually develop mammary tumors in each of the ten mammary glands [61] 
(Figure 2-1), the time of tumor onset varies among individual glands [60]. More than 
90% of mice develop pulmonary metastasis by 100 days [62]. More importantly, the 
mammary adenocarcinomas exhibit changes in biomarkers and expression patterns of 
various MMPs similar to those observed in human breast cancer patients [59, 63-67]. 
Therefore, this model was chosen to ascertain the role of AM9D as a pharmacologic 
inhibitor of MMP-9.   
 
All animal experiments were conducted following approval by the University of 
Tennessee Health Science Center Institutional Animal Care and Use Committee 
(IACUC). FVB/Nj female mice were obtained from Jackson Laboratory (Bar Harbor, 
ME) and crossed with PyMT positive FVB males. The offspring were genotyped by 
real-time PCR on a Roche LC 480 LightCycler using the following primers and universal 
probe library (UPL), probe #11 (Left primer: 5’ AACCCGAGTTCTCCAACAG 3; Right 
primer: 5’ TCAGCAAC ACAAGGATTTC 3’) to identify MMTV-PyMT positive 
females. Female mice were palpated once a week beginning at approximately 4 weeks of 
age and palpable tumors were measured in two dimensions (longest diameter and shortest  
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Figure 2-1. Mouse mammary glands.  
 
This is a basic diagram of the 10 mouse mammary glands and possible place of tumor 
development in the MMTV-PyMT transgenic mouse model. Reprinted with permission 
from Ward J. The Virtual Mouse Necropsy. Comparative Medicine Branch, NIAID, NIH. 
Accessed March 25, 2010. http://icg.cpmc.columbia.edu/cattoretti/Protocol/ 
FilesInPdf/NCIVetp.pdf. 
 
 
width) with digital calipers. Tumor volume was calculated using the formula, tumor 
volume=(width
2
x length)/2. When each transgenic female developed at least three 
palpable tumors of dimensions of 3 mm x 5 mm, which typically occurred at 8 weeks of 
age, each tumor was injected intratumorally with 5 ?l PBS containing either 10 or 25 ?g 
of AM9D or control DNAzyme using a Hamilton syringe mounted with a PT2, 26G 
needle. Tumors identified at approximately 8 weeks of age were injected once per week 
for a total of four weeks of therapy, and the site of intratumoral injection was varied to 
ensure that all areas of the tumor were exposed to the AM9D or control DNAzyme. 
Palpable mammary tumors that arose after the first intratumoral treatment in other 
mammary glands of the same mice were left untreated. For each cohort, transgenic 
females with a combined number of at least 9 tumors of comparable size were utilized 
(AM9D, 10 ug, n= 2 mice, 9 mammary tumors; AM9D, 25 ?g, n=2 mice for a total of 10 
mammary tumors and control DNAzyme, 10 or 25 ?g, n=4 mice, 12 mammary tumors). 
The above experiment was repeated using 25 ?g of either AM9D (2 mice; 12 tumors) or 
control DNAzyme (2 mice; 9 tumors) and the results were included in the calculation of 
tumor endpoint weight reported.  
  
 Tumor growth was monitored weekly by caliper measurement. All animals were 
euthanized one week after the last DNAzyme treatment (typically at 12 weeks of age). At 
necropsy, tumors were removed, final tumor dimensions were measured by calipers, and 
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the tumor wet weight was determined. Tumors were then either flash frozen in liquid 
nitrogen, or fixed in 4% paraformaldehyde overnight, followed by cryoprotection in 25% 
sucrose for several days. Cryoprotected tumors were then washed with 0.1% PBS prior to 
embedding in OCT compound and preparation of 8 micron frozen sections.  
  
 
In Situ Hybridization 
 
 The presence of DNAzymes in mammary tumor slices was detected by in situ 
hybridization using 5’ end fluorescently labeled anti-AM9D sense oligonucleotides 
(5’-CGACCTCAAtcgttgtagctagccTGGcACCAC-3’) as a probe. The tumor slices were 
incubated with 3 ?g of probe in hybridization buffer consisting of 25% formamide, 2X 
SSC, 0.5 mg/ml Salmon Sperm DNA, 1X Denhart’s solution, 100 mM DTT and 10% 
Dextran Sulfate, overnight at 42 ˚C. The slides were then washed twice with 2xSSC, 
0.1% SDS for 5 min at RT followed by two washes with 2x SSC, 25% Formamide for 20 
min at 45 ˚C, dried at RT, coverslipped and visualized by fluorescent and confocal 
microscopy.  The nucleus was visualized by addition of DAPI/anti-fade to each slide.       
 
 
Histology and Immunohistochemistry 
 
 Mammary tumor sections were stained with hematoxylin and Eosin Y (H&E; 
Fisher Scientific, Suwanee, GA).  To block non-specific staining for 
immunohistochemistry, sections were treated with 2% BSA in 1X PBS/0.2% Triton 
X-100. Tumor vasculature was then visualized using rat anti-mouse CD31 antibody 
(1:50) (BD Biosciences, San Jose, California) and Alexa Fluor-594 goat anti-rat IgG 
(H+L) secondary antibody (Invitrogen, Carlsbad, CA). Stromal cells (myofibroblasts) 
were detected by incubating the sections with anti- ?-smooth muscle actin antibody at 
1:250 dilution (Sigma St. Louis, MO) overnight at 4°C and Alexa Fluor 488 goat 
anti-mouse IgG2a (Invitrogen, Carlsbad, CA) secondary antibody at 1:500 dilution, for   
1 h at room temperature. MMP-9 protein was detected using a rabbit anti-mouse MMP-9 
antibody at a 1:200 dilution (Santa Cruz) overnight at 4°C followed by Alexa Fluor-594 
goat anti-rabbit IgG antibody (1:500) at room temperature for 1h. CD31 and caspase-3 
stained sections were blindly reviewed and grouped depending on their degree of red 
(CD31) and green (caspase-3) positive staining. MMP-9 stained slides were quantified by 
taking z-stack images and using image J.  Digital images were captured using a Bio-Rad 
Confocal Laser Scanning Microscope, using the Lasersharp 2000 software.  
 
 
Statistical Analysis 
 
 All data are expressed as mean ± standard deviation or standard error. Data were 
analyzed with SSPS software (SigmaStat version 2.03) using one-way analysis of 
variance (ANOVA). Tumor growth over time among three groups was analyzed by 
two-way ANOVA using Prism software (Graphpad version 4.0b).  In all cases, p values  
<0.05 were considered statistically significant. 
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RESULTS 
 
 
MMP-9 Is Expressed in Mammary Tumors of MMTV-PyMT Mice 
  
 To confirm the presence of MMP-9 protein in late-stage mammary carcinomas, 
tumors were harvested from MMTV-PyMT transgenic females, at 12 weeks of age. 
Tumor sections were stained with antibodies to both ?-smooth muscle actin (SMA), a 
marker for stromal myofibroblasts, and MMP-9. Immunohistochemical analysis 
demonstrated the presence of MMP-9 in stroma and in other areas, which could be tumor 
epithelium, recruited immune cells, and endothelium (Figure 2-2).  
 
 
DNAzyme In Vivo Stability 
 
 Prior to testing AM9D for its effect on mammary tumor growth, the in vivo 
stability and cellular uptake of naked DNAzyme molecules was examined by 
intratumorally injecting tumor-bearing MMTV-PyMT transgenic female mice with 
fluorescently labeled AM9D (25 ?g) suspended in PBS.  The animals were then 
sacrificed at different time intervals post AM9D injection, and mammary tumors were 
harvested, sectioned, and viewed under fluorescent microscope.  Fluorescently labeled 
oligonucleotides could be easily detected in a diffuse pattern within the tumor for up to 
14 days after injection (Figure 2-3).  Moreover, the AM9D could also be detected in 
adjacent, non-injected mammary tumors of the same mouse (Figure 2-3b), indicating a 
wide distribution pattern than might be expected from intratumoral injection. Therefore, 
the DNAzymes are stable in vivo and can efficiently distribute within the injected tumor 
and to a nearby non-injected tumor. 
 
 
 
 
 
Figure 2-2. MMP-9 in MMTV-PyMT mice mammary tumors. 
 
Immunohistochemical staining for MMP-9 in mammary tumor sections. Tumors were 
resected from MMTV-PyMT mice and double stained with antibodies to ?-smooth 
muscle actin to detect stromal cells (a) and MMP-9 (b). When channels were merged (c), 
these data show that MMP-9 is present in both stromal cells and in other areas. 
Magnification 200X. Scale bar in (c) is equivalent to 100 ?m. 
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Figure 2-3. Stability of DNAzyme in mammary tumors.  
 
Mammary tumors were injected as described in the methods with fluorescently labeled 
AM9D and resected at either (a) 7 days, (b) 10 days, or (c) 14 days post-injection. (e) 
Mammary tumor injected with unlabeled DNAzyme was used as a negative control. Of 
note, (d) DNAzyme injected into the 2R tumor of a mouse was found to be distributed to 
an adjacent, non-injected mammary tumor, 3R, which had emerged after injections were 
first initiated. Scale bar in (d) is equivalent to 100 ?m. 
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Effect of AM9D Treatment on Final Tumor Load 
  
 The efficacy of AM9D to reduce breast tumor volume in MMTV-PyMT 
transgenic mice was tested by directly injecting two concentrations (10 ?g or 25 ?g) of 
AM9D or control DNAzyme into mammary tumors of transgenic females bearing at least 
3 tumors per mouse, each at an early palpable size (~3 mm x 5 mm), once a week for 4 
weeks. Tumor palpations were performed weekly to determine changes in tumor volume 
over time. The rate of tumor growth in tumors treated with 25 ?g of AM9D (n=12 
tumors) was slower than that of the untreated tumors (n=7 tumors) or DNAzyme control 
treated (n=9 tumors) tumors (Figure 2-4a). Although, the observed difference in tumor 
growth over time in control and AM9D treated groups was not significant at early stage 
of growth (8-11 weeks of age; 2-way ANOVA, p>0.05), the difference was statistically 
significant at 12 weeks of age (Figure 2-4), the study endpoint.  The p values obtained for 
AM9D vs. control DNAzyme treated and untreated tumors were p<0.001 and p<0.01, 
respectively. The final tumor volume of AM9D treated tumors was significantly reduced 
compared to that of the control DNAzyme treated tumors (Figure 2-4b). In fact, 
administration of AM9D at 10 ?g was sufficient to reduce the size of the tumor by 
39.5%, which increased to 50.1% when 25 ?g of AM9D was utilized (p<0.01 for 
statistical comparison of control to 10 ?g and to 25 ?g, one-way ANOVA). 
 
Immunohistochemical analysis of the mammary tumors (Figure 2-5) confirmed 
that AM9D treatment successfully down-regulated MMP-9 protein expression.  As 
shown in Figure 2-5b, AM9D treatment reduced MMP-9 expression by 66 ± 11% in 
tumor compared to the control DNAzyme treatment (Figure 2-5a). In addition, in situ 
hybridization of the tumor tissue slices demonstrated the presence of DNAzyme in tumor 
and the surrounding tissue (Figure 2-6).  Taken together, these data show that AM9D 
efficiently decreases MMP-9 expression in tumors, which is responsible for the observed 
anti-tumor effects. 
 
 
Effect of AM9D on Angiogenesis and Apoptosis  
 
 MMP-9 has been shown to play a role in tumor progression through increase of 
bioavailability of VEGF and other factors that promote angiogenesis [30]. To determine 
the mechanism of tumor volume reduction by AM9D, the tumor slices were stained for 
CD-31 and for caspase-3 to assess the effect of AM9D on angiogenesis and apoptosis, 
respectively. AM9D treatment substantially reduced the number of blood vessels in the 
tumor as demonstrated by the lack of robust CD-31 immunostaining in the AM9D treated 
group (Figure 2-7c) versus untreated (Figure 2-7a) or the control DNAzyme treated 
(Figure 2-7b) groups.  These data suggest that anti-angiogenic effect of AM9D delays 
tumor growth over time and tumor volume at our study endpoint. Moreover, our data also 
indicate that AM9D induces apoptosis in the tumor.  This is based on the observation that 
only AM9D treated tumors contain a large number of caspase-3 positive cells  
(Figure 2-8).  Therefore, AM9D therapy can simultaneously induce tumor cell apoptosis 
and decrease stromal cell neo-angiogenesis. 
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Figure 2-4. Effect of AM9D on the rate of tumor growth and final mean tumor 
volume.  
 
(a) AM9D-treated tumors (?) grew at a slower rate than either untreated tumors (no 
injections, ?) or tumors treated with control DNAzyme (?). The difference between 
control DNAzyme treated and untreated tumors is not significant at 8-11 weeks of age 
(p>0.05), but is statistically significant at 12 weeks of age (p<0.05), the study endpoint. 
(b) Weekly intratumoral treatment of transgenic mice with 10 ?g (n=9 tumors) or 25 ?g 
AM9D (n=21 tumors) per tumor reduced mean tumor burden by 39.5% or 50.1%, 
respectively, when compared to tumors treated with control DNAzyme (n=24 tumors) 
(p<0.01 ANOVA).  
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Figure 2-5. Effect of AM9D on MMP-9 protein expression in MMTV-PyMT 
mammary tumors.  
 
Mammary tumors treated with either 25 ?g control DNAzyme or AM9D were stained 
with an anti-MMP-9 antibody. Mammary tumors treated with (b) AM9D for 4 weeks 
showed lower MMP-9 staining compared to (a) those treated with 25 ?g control 
DNAzyme for 4 weeks.  Images are shown at 200x magnification; scale bar is equivalent 
to 100 ?m. 
 
 
 
 
 
Figure 2-6. Fluorescent in situ hybridization. 
 
In situ hybridization performed on 25 ?g AM9D-treated mammary tumors at study 
endpoint. (a) Green signal indicates the presence of AM9D DNAzyme (arrows) and (b) 
DAPI was used to detect cell nuclei. (c) Images (a) and (b) merged. Magnification 400X.  
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Figure 2-7. AM9D reduces tumor vasculature.   
 
Immunohistochemical staining for CD31 (red) to detect the vasculature in mammary 
tumors harvested from mice treated with 25 ?g of AM9D (c and e) or control DNAzyme 
(b and d). A subset of sections was also counterstained with DAPI (d and e). Untreated 
tumors (a) and tumors treated with control DNAzyme (b and d) contained more blood 
vessels than did tumors treated with AM9D (c and e). Images are shown at 200x (a-c) or 
400x (d and e) magnification. Scale bar is equivalent to 100 ?m (a-c) and 50 ?m (d and 
e). 
 
 
 
 
  
Figure 2-8. AM9D induces apoptosis. 
 
Immunohistochemical staining of mammary tumors harvested from mice treated for four 
weeks with 25 ?g (a) control DNAzyme or (b) AM9D for caspase-3 indicate AM9D 
treatment (b) induces apoptosis in mammary tumors. Caspase 3 staining is shown in 
green and nuclei are stained blue with DAPI. Very few caspase-3 positive cells (green) 
were detected in tumors treated with control DNAzyme (a) compared to AM9D-treated 
tumors (b), where large regions stained positive for caspase-3. Scale bar is equivalent to 
100 ?m.  
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DISCUSSION 
 
 In this study, we show for the first time, that the down regulation of MMP-9 in 
mammary tumors by a novel anti-MMP-9 DNAzyme molecule results in a significant 
reduction in final tumor volume in the MMTV-PyMT transgenic mouse model of breast 
cancer. Down regulation of MMP-9 by AM9D was accompanied by a decrease in 
MMP-9 expression, decreased angiogenesis and increased apoptosis. Moreover, these 
effects were accomplished by intratumoral injection of naked DNAzyme without the use 
of any carriers. Together, these data indicate that inhibition of MMP-9 expression by 
DNAzyme has potential as a novel therapeutic modality to decrease growth and invasion 
of carcinoma cells in the clinical setting. 
 
 It is known that MMP-9 plays a key role in angiogenesis by releasing VEGF [30] 
and that its down regulation induces apoptosis by stimulating ERK pathway [32]. Martin 
et al. [68] have demonstrated that spontaneous lung metastases decreased by 80% in 
MMTV-PyMT MMP-9 null mice compared to MMTV-PyMT MMP-9 wild type mice. In 
addition, the lung tumors developed in MMTV-PyMT MMP-9 wild type mice are larger 
in size and are more highly vascular compared to those tumors that developed in 
MMTV-PyMT MMP-9 null mice. Thus, the data presented here is consistent with the 
above studies and demonstrate that down regulation of MMP-9 by AM9D also affects 
tumor growth via inhibiting angiogenesis and inducing apoptosis (Figures 2-7 and 2-8) as 
demonstrated by lack of CD31 staining and the enhanced presence of caspase3 in AM9D 
treated tumors. 
 
 Our results are consistent with those of Almholt, et al. [67] which showed that the 
broad-spectrum MMP inhibitor Galardin/GM6001, significantly reduced primary 
mammary tumor growth by 50% and reduced lung metastasis by more than 100-fold in 
the MMTV-PyMT model. However, contrary to broad-spectrum MMP inhibitors, 
including GM6001, AM9D treatment specifically down regulates MMP-9 without 
affecting the expression of other members of the MMP family (Figure 1-3b and 1-3c). As 
demonstrated by the extent of cytoxicity of broad spectrum MMP inhibitors in prior 
clinical trials [41, 46, 47], total inhibition of MMPs is not practical, since various MMPs 
can exert both pro-tumorigenic and anti-tumorigenic properties [17].  In addition, MMPs 
are critical for normal physiological processes, such as bone growth and remodeling, 
ovulation, and wound healing [19].  Further, in comparison with GM6001 [67], the 
intratumoral injection of AM9D not only reduced the required frequency of therapy; it 
was equally efficient in reducing final tumor size.  Once weekly, intratumoral injections 
of 25 ?g AM9D (1.25 mg/kg) was sufficient to reduce the size of these spontaneously 
developed tumors by 50% as compared to the 51% tumor reduction observed following 
daily administration of 100 mg/kg of GM6001. Thus, the high degree of specificity for 
targeting MMPs, the lack of in vivo toxicity and the increased efficacy of AM9D as 
compared to broad spectrum inhibitors should enhance the clinical response of solid 
tumors, including breast tumors, while evading the serious side effects experienced with 
systemic therapy based on broad-spectrum MMP inhibitors. 
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CHAPTER 3.    DISTRIBUTION, CLEARANCE, AND CYTOTOXICITY OF 
DNAZYME 
 
 
INTRODUCTION 
 
 Enzymatic DNA molecules have been used recently in cell based assays and 
preclinical animal studies to treat various cancers. We have shown that intratumoral 
injections of anti-MMP-9 DNAzyme (AM9D) reduced mammary tumor burden in 
MMTV-PyMT transgenic mice by 50% (Chapter 2). As described previously, 
DNAzymes designed to specifically target Aurora kinase A inhibited growth of human 
prostate cancer in vivo [52]. A DNAzyme targeting VEGF2 mRNA led to a 75% 
reduction in tumor size compared to saline treated control [53] and treatment of 
MDA-MB-231 xenograft solid tumor model with an EGR-1 mRNA specific DNAzyme 
(DzF) resulted in inhibition of tumor growth compared to saline treated control [69].  
However, all of these preclinical studies of tumor growth were conducted via 
intratumoral injections. While intratumoral injections can illustrate the promise of 
DNAzymes relative to target specificity and therapeutic potential, it is impracticable for 
clinical trials in humans. Thus, successful systemic application of DNAzymes in 
pathophysiological and therapeutic studies requires prior demonstration of significant 
uptake of DNAzyme by the target tissues. Moreover, to optimize DNAzyme regimens, 
tissue distribution and clearance must also be studied in vivo.   
  
 In this body of work, we have shown, for the first time, that naked AM9D is safe 
when administered systemically to healthy FVB mice and distributes to all organs of 
healthy mice and the Mouse Mammary Tumor Virus-polyoma middle T antigen 
(MMTV-PyMT) transgenic mouse model of breast cancer.  
 
 
MATERIALS AND METHODS 
 
 
Synthesis of 
35
S-radiolabeled Oligonucleotides 
 
 The DNAzyme molecules were labeled at the 5’ end using ATP?- 35S (Perkin 
Elmer, Waltham, MA) and T4 polynucleotide kinase (Promega, Madison, WI). The 
35
S-labeled DNAzyme ([
35
S]-DNAzyme) was then purified using a centri-10 column 
(Applied Biosystems, Carlsbad, CA).  [
35
S]-DNAzyme was dissolved in sterile Phosphate 
Buffered Saline (PBS). The concentration of the solution was adjusted so that 100 ?l 
administered to 20g mice resulted in a dose of 10 mg/kg of body weight (specific activity, 
0.275 mci/kg). [
35
S]-DNAzyme was mixed with unlabeled DNAzyme to obtain the 
desired concentration.   
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Animal Experiments 
 
 All animal studies were done in accordance with the guidelines established by the 
Animal Care and Use Committee at The University of Tennessee Health Science Center.  
Twenty-three 8 week-old female FVB mice weighing 20-25 g and 19 MMTV-PyMT 
transgenic mice (FVB strain) bearing mammary tumors of various sizes and weighing 
17-22 g were used in this study. MMTV-PyMT transgenic mice develop tumors in 6-8 
weeks of age.  Mice bearing a range of early (<500 mm
3
) and late stage (>750 mm
3
) 
tumors were used.  
 
 
Systemic Distribution 
 
 Normal Mice. [
35
S]-DNAzyme, 100 ?l (10 mg/kg; 0.275 mci/kg) in PBS was 
administered into 23 healthy anesthetized mice via tail vein injection.  Three animals 
were placed in metabolism cages, immediately following injection, for 7 days (168 h).  
The urine and feces were collected daily for total radioactivity determination from each 
of the three animals. All samples were collected and stored at -80 ˚C until analysis. The 
remaining 20 mice were divided into 5 groups of 4 animals each and at 2, 6, 24, 48, and 
72 h following intravenous administration of  [
35
S]-DNAzyme, one group of animals was 
sacrificed and liver, heart, lung, kidney, and spleen were removed for determination of 
total radioactivity. This experiment was repeated using 6 mice divided into 2 groups of 3 
mice each. At 2 and 6 h following intravenous administration of [
35
S]-DNAzyme, one 
group of animals was sacrificed and liver, heart, lung, kidney, spleen, intestines, brain, 
pancreas, and stomach were removed for determination of total radioactivity. 
Immediately prior to sacrifice, blood samples (0.5-1 ml) were collected from anesthetized 
mice via the retro-orbital vein. 
 
 MMTV-PyMT Mice. DNAzyme was administered as above into 19 tumor 
bearing mice and these were divided into 5 groups of 3 animals each and one group of 4 
animals.  At 2, 4, 8, 24, 48, and 72 h following [
35
S]-DNAzyme administration, one 
group of animal was sacrificed. Tumor volumes were measured using calipers during the 
experiments, and after excision, wet weights were recorded. Tumors exceeding 1.37g 
were highly heterogeneous (i.e. necrotic areas and mixture of tumor consistency) and thus 
were not included in any statistical analysis of mammary tumors. Heart, lung, kidney, 
liver, spleen, and blood samples were removed for determination of total radioactivity. 
 
 
Radioactive Sample Analysis 
 
 Organs were solubilized in at least 1 ml SOLVABLE according to manufacturer’s 
instruction (Perkin Elmer) and incubated overnight at 50 ˚C. Endogenous peroxidase 
activity was quenched with 10mM EDTA and 6% hydrogen peroxide for 1 h at 50 ˚C. 
Blood samples were collected from each mouse and 200 ?l of each sample was incubated 
with 1 ml SOLVABLE at 50 ˚C for 1 h. The endogenous peroxidase activity in blood was 
quenched with EDTA and hydrogen peroxide, as above.  Approximately 10 ml of 
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scintillation cocktail fluid was added to each sample and tissue radioactivity was 
measured using a Packard Tri-Carb 2900CA liquid scintillation analyzer. Counts per 
minute obtained from each sample were converted to microgram of DNAzyme 
equivalents and presented as the total ?g DNAzyme per either weight or volume of 
tissue, blood, urine, or fecal output. Initial and final rates of clearance were calculated 
based on the slope of the line obtained from plotting ?g DNAzyme per gram of tissue (ml 
blood) as a function of time (initial: 2-6 h for normal mice and 2-8 h for MMTV-PyMT 
mice, final: 24-72 h). All data were expressed as mean ± standard deviation of mean.  
The quenching effect of tissue on radioactive count was tested by adding appropriate 
amounts of [
35
S]- DNAzyme to scintillation vials containing solubilized normal organs.  
No significant tissue quenching effect was observed. 
 
 
Cytotoxicity 
 
 Healthy mice were intravenously injected with PBS or various concentrations   
(10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) of either AM9D or Scrambled 
DNAzyme. Five mice per dosage for a total of 35 mice were used. The mice were 
sacrificed 7 days after DNAzyme administration. Following dosing, animals were 
observed daily for signs of toxicity including trouble grooming, lack of food 
consumption, and any other signs of lethargy; none was observed.  At necropsy, liver, 
heart, lung, kidney, and spleen were collected and fixed in 4% paraformaldehyde, 
impregnated with 25% sucrose that acts as a cryoprotectant, and were processed for 
histopathological evaluation (standard light microscopic examination of hematoxylin and 
eosin-stained tissue slides).  
 
 
RESULTS 
 
  
Kinetics of DNAzyme in Normal Mice 
 
 The systemic distribution of DNAzyme in mice and its rate of clearance were 
determined by injecting naked [
35
S]-AM9D (10 mg/kg) in PBS via tail vein into healthy 
FVB mice and the amount of radioactivity present in blood and different organs was 
measured as a function of time. Figure 3-1a illustrates the tissue/blood distribution time 
profile of DNAzyme in mice.  AM9D injected via tail vein in mice is distributed to all 
major organs; liver, heart, spleen, kidney, and lungs. Two hours after DNAzyme 
injection, approximately 10% of the total DNAzyme was found in major organs  
(Table 3-1). The order of percentage accumulation was: blood>liver>kidney>lung> 
spleen>heart. Blood contained a majority of DNAzyme with 6.3% of the total DNAzyme 
in the first 2 h and reduced to 2.1% after 6 h (Table 3-1). Studies revealed 1.8%, 1.1% 
and 0.4% of total DNAzyme injected was delivered to liver, kidney, and lung, 
respectively. Finally, spleen and heart contained 0.21% and 0.2% of total DNAzyme in  
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Figure 3-1. Distribution and elimination profile of [
35
S]-DNAzyme in normal 
mice. 
 
(a) Distribution profile for [
35
S]-DNAzyme in tissue and blood. The tissue concentration 
of [
35
S]-DNAzyme derived radioactivity is based on ?g equivalent DNAzyme/g of organ 
and is the mean (+/- stdev) of 3-4 mice for each tissue. Blood concentrations are the mean 
values from all samples collected at each time point throughout the experiment. The 
DNAzyme blood concentration was first corrected for total blood in mouse based on the 
animal’s weight and a mean of blood volume of 79 ?l/g body weight. Then, for 
calculation of ?g DNAzyme/g of blood, 1 ml blood was assumed to be equal to 1 g. (b) 
Elimination profile for [
35
S]-DNAzyme. The urine and fecal concentrations are mean 
values calculated for the total output from three mice each day for a total of 7 days.  
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Table 3-1. Tissue distribution of [
35
S]-DNAzyme in normal mice presented in 
average percentage of total DNAzyme. 
 
Tissue       2 h
 
     6 h     24 h     48 h      72 h    7 days 
        
    2.198    1.375    0.281   0.141     0.108    0.185 
(1.59-2.55) (.94-2.2) (.16-.46) (.12-.16)   (.05-.14)  (.09-.31) 
Liver 
      
   0.205    0.144   0.042   0.022    0.016    0.005 
(.15-.26) (.06-.22) (.03-.05) (.01-.02) (.01-.03) (.003-.007) 
Heart 
      
   0.215    0.08   0.029    0.02   0.021   0.008 
(.17-.26) (.05-.14) (.02-.04) (.01-.02) (.017-.023) (.005-.01) 
Spleen 
      
Kidney    1.132   0.575   0.209   0.138   0.109   0.048 
 (.90-1.5) (.33-.84) (.17-.24) (.11-.16) (.09-.12) (.03-.07) 
       
Lung   0.366   0.216   0.061   0.043   0.033   0.01 
 (.28-.51) (.15-.30) (.04-.07) (.04-.05) (.02-.04) (.008-.01) 
       
Blood   6.264   2.103   0.305   0.143   0.102   0.068 
 (3.0-11.4) (.96-3.3) (.16-.42) (.08-.17) (.09-.13) (.05-.08) 
       
Numbers in
 
parentheses give the range of data. 
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2 h post injection, respectively. The majority of the DNAzyme was cleared from these 
organs within the first 24 h. Thirty-one percent of the delivered dosage of 
[
35
S]-DNAzyme was cleared from the system via feces and urine over a period of 72 h.  
 
 This experiment was repeated for time points 2 and 6 hours after DNAzyme 
injections to assess distribution of DNAzyme to the following additional organs: brain, 
pancreas, stomach, and intestines. Similar to the above experiments, 100 ?l of 
[
35
S]-DNAzyme (10 mg/kg; 0.275 mci/kg) in PBS was administered into 6 healthy 
anesthetized mice via tail vein injection. The 6 mice were divided into 2 groups of 3 
animals each and at 2 and 6h following intravenous administration of  [
35
S]-DNAzyme, 
one group of animals was sacrificed and liver, heart, lung, kidney, spleen, intestines, 
brain, pancreas, and stomach were removed for determination of total radioactivity 
(Figure 3-2). As shown in Figure 3-2, 2 and 6 h after injection, in addition to the organs 
previously described, DNAzyme can be found in brain (0.312 ?g and 0.248 ?g 
DNAzyme/g), pancreas (1.147 and 1.0 ?g DNAzyme/g), intestines (11.11 and 11.42 ?g 
DNAzyme/g), and stomach (11.92 and 7.41 ?g DNAzyme/g). This data demonstrates that 
DNAzyme molecule is capable of passing the blood brain barrier and suggests that it can 
be used as a therapeutic agent against brain tumors, as well as tumors which affect the 
pancreas, liver, and stomach (gastrointestinal stromal tumor).   
 
 The rate of initial clearance (from 2-6 h) and final clearance (from 24-72 h) of 
DNAzyme from different organs were calculated based on the amount of DNAzyme 
remaining in tissues as a function of time (Table 3-2). The rate of initial clearance of 
DNAzyme from blood was faster than kidney followed by spleen>liver>heart?lung 
 
 
 
 
 
Figure 3-2. Distribution profile of [
35
S]-DNAzyme in additional organs of normal 
mice. 
 
The tissue concentration of [
35
S]-DNAzyme derived radioactivity is based on ?g 
equivalent DNAzyme/g of organ and is the mean (+/- stdev) of organs isolated from 3 
mice.  
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Table 3-2. Rate of [
35
S]-DNAzyme initial and final clearance in normal mice.  
 
Tissue Initial clearance
a
 Final clearance
b
 
  ?g DNAzyme/g tissue/h ?g DNAzyme/g tissue/h 
Liver 0.281 0.0039 
Heart 0.149 0.0052 
Spleen 0.442 0.0023 
Kidney 0.495 0.0074 
Lung 0.143 0.0022 
Blood 5.202 0.0123 
 
a
Initial clearance is between 2-6 h. 
b 
Final clearance is between 24-72h. 
 
 
(Table 3-2). The rates of initial and final clearance of DNAzyme from kidney were 0.495 
?g DNAzyme/g of tissue/h and 0.0074 ?g DNAzyme/g of tissue/h, respectively. The rate 
of initial clearance of AM9D from heart and lung are equivalent, however, DNAzyme is 
retained in lung longer as its rate of final clearance in lung is approximately 2-fold slower 
than that of the heart (Table 3-2). 
  
 Fecal excretion represented the major pathway of DNAzyme elimination   
(Figure 3-1b). The amount of DNAzyme excreted in feces (32%) is 3-fold greater than 
the amount released from urine (11%) over the 7-day period. As expected, DNAzyme 
excretion was time-dependent with the majority being eliminated in the first 72 h.  
 
 
Kinetics of DNAzyme in Mammary Tumor bearing Mice 
 
 Female MMTV-PyMT transgenic mice bearing early to late stage mammary 
tumors were used to test the distribution of DNAzyme to mammary tumors. Naked 
[
35
S]-DNAzyme in PBS was administered to tumor bearing animals via tail vein 
injections, animals were then sacrificed at different times and the amount of 
[
35
S]-DNAzyme present in different organs, blood, and mammary tumors were 
determined as a function of time (Figure 3-3a and b). The order of percentages 
of [
35
S]-DNAzyme accumulation in different organs of MMTV-PyMT mice was 
mammary tumor>liver?blood>kidney>spleen>lung>heart. [35S]-DNAzyme concentration 
in the mammary glands was markedly higher than in other tissues. In these mice, 4.1%  
of the total injected DNAzyme was accumulated in the mammary tumors in 2 h  
(Table 3-3). Mammary tumors of transgenic mice were of varying sizes and the amount  
28 
 
 
 
Figure 3-3. Distribution profile of [
35
S]-DNAzyme in MMTV-PyMT mice. 
 
(a) Transgenic mice developed on average 7 mammary tumors per mouse and the mean 
value of tumor for 3-4 mice were calculated. Small and medium size tumors displayed 
different accumulation and clearance profiles. For this reason, tumors weighing less than 
1.37 g were divided into two categories, small (<0.7 g) and medium (?0.7 g, ?1.37 g). 
Tumors exceeding 1.37 g were excluded. (b) The tissue concentration of [
35
S]-DNAzyme 
derived radioactivity is based on ?g equivalent DNAzyme/g of organ and is the mean of 
3-4 mice for each tissue. The blood samples were collected from all mice. The DNAzyme 
blood concentration was first corrected for total blood in mouse based on the animal’s 
weight and a mean of blood volume of 79 ?l/g body weight. Then, for calculation of ?g 
DNAzyme/g of blood, 1 ml blood was assumed to be equal to 1 g.  
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Table 3-3. Tissue distribution of [
35
S]-DNAzyme in MMTV-PyMT mice presented in average percentage
a
 of total 
DNAzyme.  
 
Tissue      2 h     4 h     8 h     24 h      48 h      72 h 
         
    3.89     3.31     1.72     0.72     0.46     0.31 
(2.7-5.76)  (3.2-3.5) (1.5-1.9)  (.47-1.0) (.419-.529) (.215-.355) 
Liver 
       
    0.33     0.24     0.17     0.05    0.018    0.009 
 (.27-.41) (.17-.30) (.11-.25)  (.03-.07) (.012-.022) (.007-.013) 
Heart 
       
    0.54     0.4     0.26    0.13     0.03     0.025 
 (.27-.88) (.35-.46) (.21-.32) (.08-.24) (.029-.038) (.019-.028) 
Spleen 
       
   1.27     1.1     0.63     0.3     0.15     0.14 
(.83-1.9) (.93-1.3) (.54-.69) (.03-.55) (.13-.16) (.011-.016) 
Kidney 
       
    0.38    0.28    0.184    0.07    0.051    0.029 
(.18-.77) (.18-.39) (.1-.3) (.04-.1) (.046-.055) (.022-.032) 
Lung 
       
Mammary      4.1     5.5     5.2     1.3    0.049    0.038 
Tumor 
b
 (.06-9.2) (.1-8.5) (3.3-7.2) (0.5-2.3) (.011-.105) (.020-.059) 
         
  3.52    2.97   1.64    0.69    0.216    0.115 
(3.4-3.8) (2.4-3.5) (1.5-1.7) (.52-.86) (.168-.274) (.080-.166) 
Blood 
            
a
Numbers in parentheses give the range of data. 
b
 Tumors larger than 1.37 g were excluded from calculations. Data range in mammary tumors is attributed to range of tumor sizes. 
The large range of data in organs, in some cases, is attributed to technical error of injection.
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of DNAzyme accumulated in mammary tumors was proportional to the weight of the 
tumor burden (Figure 3-4).  
 
 Interestingly, the accumulated DNAzyme in the mammary tumor is initially 
cleared at a slower rate compared to the other organs, with rate of initial clearance (2-8 h 
post DNAzyme injection) of 0.068 ?g DNAzyme/g tissue/h (Table 3-4). The mammary 
tumors characterized as small tumors (<0.7 g) continue accumulating DNAzyme 2-4 h 
post injection (Figure 3-3a). This corresponds with the initial clearance of DNAzyme 
from blood 2-4 h post DNAzyme injection (Figure 3-3b). Similar to DNAzyme 
distribution in normal mice, the percentages of the total DNAzyme accumulated in blood, 
liver, kidney, lung, spleen, and heart, 2 h post DNAzyme injection, was 3.5%, 3.9%, 
1.3%, 0.4%, 0.5% and 0.3%, respectively (Table 3-3).  However, the rate of initial 
clearance of DNAzyme from spleen was slower than blood but faster than any other 
organs tested followed by Liver?Kidney>Heart>Lung>Mammary tumors (Table 3-4). 
The majority of the DNAzyme was eliminated from the organs and blood within the first 
24 h (Figure 3-3b). The rate of initial clearance from liver and kidney was found to be the 
same (4.3 ?g DNAzyme/g tissue/h) during the first 8 h of administration and slightly 
increased in kidney between 24-72 h.  In heart, the rate of clearance in 2-8 h (initial) and 
24-72 h (final) post administration was 2 and 3.4-folds faster than that in lung, 
respectively (Table 3-4). 
 
 
Cytotoxicity of Intravenous Injection of AM9D in Healthy Mice   
 
 Safety of DNAzyme delivered intravenously in healthy FVB mice was 
determined using single injection of escalating concentrations of AM9D or control 
DNAzyme (10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) in PBS. PBS was used as 
a control. Seven days post DNAzyme injection, mice were sacrificed and liver, spleen, 
lung, heart, and kidney were isolated and analyzed for cytotoxicity by H&E staining 
(Figure 3-5). All tissues were evaluated (in a blinded manner) for evidence of capillary 
leakage, acute cellular damage including necrosis or apoptosis, acute inflammation and 
mitotic activity by a pathologist.   No evidence of acute cytotoxicity, mitogenesis, cell 
death, local or widespread, was observed in the organs examined. 
 
 
DISCUSSION 
 
 These results indicate that DNAzyme oligonucleotides could be delivered 
intravenously to all organs without the use of lipids or other carrier molecules, as naked 
DNAzyme was injected, and that the [
35
S]-AM9D was present in various organs 
including mammary tumor tissues and organs of high incidence for metastasis (i.e. lung).  
In addition, mammary tumors can take up the DNAzyme faster and retain it longer than 
any other organs.  Together, these data suggest that DNAzymes can be useful as a 
therapeutic agent to treat human patients with breast cancer or any other solid tumors.
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Figure 3-4. Distribution of [
35
S]-DNAzyme in MMTV-PyMT mammary tumors.  
 
Total tumor burden was measured in grams and the total ?g DNAzyme found in tumors 
were calculated. DNAzyme injected into mice bearing tumors of varying sizes show a 
proportional correlation between tumor size (all tumors combined per mouse) and 
DNAzyme distribution (Y=1.4045x-0.4159, R
2
=0.7764). 
 
 
Table 3-4. Rate of [
35
S]-DNAzyme initial and final clearance in mice with 
mammary tumors.  
 
Tissue Initial clearance
a 
Final clearance
b 
  ?g DNAzyme/g tissue/h ?g DNAzyme/g tissue/h 
Liver 0.434 0.0052 
Heart 0.277 0.0082 
Spleen 0.653 0.0278 
Kidney 0.426 0.0063 
Lung 0.134 0.0024 
Mammary 
Tumor
c
 
0.068 0.0128 
     
Blood 1.507 0.0569 
      
a 
Initial clearance is between 2-8 h.  
b 
Final clearance is between 24-72 h. 
c 
Tumors larger than 1.37 g were excluded from calculations. 
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Figure 3-5. Pathology of organs from mice injected with AM9D, control 
DNAzyme, or PBS. 
 
Mice injected with PBS, or various concentrations of control or AM9D showed no 
difference in organ pathology. The tissues displayed were extracted from mice that 
received the highest dose (75 mg/kg of AM9D and control DNAzyme; 400x 
magnification). 
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 Recently, DNAzymes have emerged as novel, highly selective inhibitors of gene 
expression. Although they have yet to be used in clinical trials, reports of studies 
demonstrating the efficacy of DNAzyme based cancer therapies are beginning to emerge 
[50]. However, thus far, all of the preclinical studies testing the effect of DNAzyme on 
tumor growth were via intratumoral or subcutaneous injections. In spite of the fact that 
tumor growth is an important factor in cancer progression, metastasis is ultimately the 
determining factor for cancer survival for many types of cancer [70-72]. Thus, while 
intratumoral injections can show promise as to the DNAzymes specificity to its target and 
future therapeutic capabilities, it is not feasible in humans. To advance the therapeutic 
potential of DNAzyme toward clinical trial, it is necessary to design an anti-metastatic 
DNAzyme and demonstrate its anti-metastatic potential based on its systemic 
distribution, safety and efficacy. 
 
 Expression of MMP-9, by tumor and stroma cells has been shown in breast cancer 
patients [73] and is one of the most important factors for metastatic behavior of tumor 
cells [23, 54, 74]. MMP-9 degrades type IV collagen, one of the most abundant collagens 
in the ECM [11, 75] and is involved in cell proliferation, angiogenesis, and apoptosis [9, 
10, 30]. Increasing evidence suggests that MMPs contribute to the formation of a 
microenvironment that promotes tumor growth during early stages of tumorigenesis.   
Our observation that AM9D treatment decreased MMP-9 production (Figure 1-3c and 
2-4) and reduced invasive behavior of human MDA-MB-231 cells (Figure 1-3d) 
suggested that AM9D has a great potential as an anti tumorigenic/metastatic agent. Thus, 
to utilize anti-MMP-9 DNAzyme (AM9D) as a therapeutic agent in breast cancer 
preclinical and clinical studies, healthy and MMTV-PyMT transgenic mouse model 
bearing early to late stage tumors were used to test the distribution of AM9D to different 
organs and mammary tumors. The order of percentage accumulation of DNAzyme in 
healthy mice in different organs was: blood>liver>kidney>lung>spleen>heart. In addition 
to these organs, [
35
S]-DNAzyme was also distributed to brain, intestines, stomach, and 
pancreas (Figure 3-2). Approximately, 43% of the delivered dosage of [
35
S]-DNAzyme 
was cleared from the system via feces and urine over a period of 72 h (Figure 3-1b). This 
data is consistent with Agrawal et al.’s observation that 40% of intravenously 
administered anti-sense phosphorothioate oligonucleotides complementary to HIV RNA 
in mice, is excreted in urine and 16% in feces within the first 48 h [76]. Contrary to these 
data, however, we observed a higher excretion of DNAzyme in feces than in urine 
(Figure 3-1b).  
 
 Interestingly, when [
35
S]-DNAzyme was administered to MMTV-PyMT 
transgenic mice the amount of DNAzyme accumulated in mammary tumors 2 h post 
injection was 0.6% and 0.2% higher than in either blood or liver, respectively, and its rate 
of initial clearance from mammary tissue was slower than the other organs (Tables 3-3 
and 3-4). The amount of DNAzyme accumulated in mammary tumors was proportional 
to the tumor burden (Figure 3-4), suggesting a favorable therapeutic outcome. This is 
expected considering that mammary tumors can be highly vascularized [77].  
 
 DNAzyme administered systemically is safe and at 75 mg/kg of body weight 
caused no observable mortality or organ toxicity in mice. Pathological studies did not 
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reveal any evidence of acute toxicity, mitogenesis, or cell death, local or widespread in 
any organs examined (Figure 3-5), contrary to those described for other oligonucleotides 
[78]. Several investigators have reported hepatocyte toxicity and necrosis [76, 78] and 
renal tubular structural perturbations [76] with oligonucleotide administration as low as 
20 mg/kg [78] and as high as 30 mg/kg/day over 14 days (total 420 mg/kg) [76]. This 
however, was not observed in this study. It should be noted that the delivered dosage of 
AM9D for this study (75 mg/kg) was much higher than those used in the other DNAzyme 
studies [78], however, lower than some studies which showed hepatocyte toxicity [76]. 
 
 In conclusion, systemic distribution and safety/toxicity studies revealed that the 
naked AM9D is non-toxic when systemically administered, and has favorable 
pharmacological properties with respect to intravenous administration and tissue 
distribution. Most importantly, mammary tumors can take up the naked DNAzyme. The 
amount of DNAzyme accumulates in the mammary gland is higher and its rate of 
clearance is slower than any other organs tested. These factors may permit the 
development of DNAzyme as a cancer therapeutic agent with much improved toxicity 
profiles as compared with conventional drugs. 
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CHAPTER 4.    AM9D TREATMENT OF EXPERIMENTAL METASTASIS 
 
 
INTRODUCTION 
 
 The role of MMP-9 in cancer metastasis has been widely researched. The 
treatment of DU145 prostate cancer cells with curcumin, an anti-metastatic derivative 
from tumeric, has been shown to decrease the levels of MMP-2 and -9 and lead to a 
decrease in tumor volume [79]. Curcumin treatment has also been shown to alter the 
invasive and metastatic properties of MCF10A human breast epithelial cells [80] and 
decrease metastasis to lung in a human breast cancer xenograft model [81] by decreasing 
the levels of MMP-9 and COX-2. According to Eiseler, et al., highly invasive breast 
cancer human tissue samples, regardless of stage and progesterone or estrogen 
dependence, were shown to have reduced Protein Kinase D1 (PKD1) expression in 
greater than 95% of the tumor samples compared to normal breast tissue [82]. 
Furthermore, the invasiveness of MDA-MB-231 cells was reduced by the re-expression 
of PKD1, which was shown to negatively regulate MMP-9, the mainly expressed MMP 
in MDA-MB-231 cells. [82]. Thus, PKD1 regulates breast cancer cell invasion through 
regulation of the expression of MMP-9. Furthermore, Chen et al. provided evidence that 
the presence of increased levels of MMP-9 in integrin alpha1-null mice enhanced the 
number of tumors on lung but these tumors were smaller compared to lung tumors in WT 
counterparts [83]. They also showed that inhibition of MMP-9 by doxycyclin in these 
alpha1-null mice led to reduced number of lung colonies but bigger tumors were 
observed. This was because reduced MMP-9 plasma levels led to decreased generation of 
angiostatin, an anti-angiogenic molecule. Thus, while an MMP-9 inhibitor may be useful 
in treating tumor cell migration, invasion, and metastasis it may adversely increase 
growth and vascularization of tumors intravenously introduced to lung.  
  
 In previous Chapters of this body of work we have shown that, in accordance with 
the findings of Eiseler, et al. [82], down-regulation of MMP-9 by AM9D decreases the 
invasive potential of MDA-MB-231 human breast cancer cells. We have also shown the 
presence of MMP-9 in MMTV-PyMT mammary tumors (Figure 2-2) and presented 
evidence that MMP-9 expression is significantly lower in AM9D treated tumors 
compared to control (Figure 2-5), leading to a reduction in final tumor load (Figure 2-4). 
Furthermore, AM9D when injected via the tail vein of normal and MMTV-PyMT mice 
was shown to be distributed to all major organs including lung and was tested to be safe 
up to 75 mg/kg of body weight (1500 ?g/100 ?l of PBS).  
 
 MMP-9 is involved in tumor cell extravasation and colonization [84-87]. Thus, 
down-regulation of MMP-9 by intravenous administration of AM9D was expected to 
inhibit the tumor cells from participating in extravasation and seeding of the tumor cells 
in the lungs. Consequently, the number of lung colonies will be reduced and further lead 
to increased survival of mice compared to control treated counterparts.  
 
Using an experimental lung metastasis animal model, we have shown that both 
AM9D and control DNAzyme treatment were equally effective in inhibiting early stage 
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experimental metastasis. However, mice treated with these two cohorts did not show 
statistically significant overall increased survival. 
 
 
MATERIALS AND METHODS 
 
 
Establishing eIF1 alpha-Luciferase2 Mammary Tumor Epithelial Cells 
(luc-MTECs)
1
  
 
 Several late stage mammary tumors (>500 mm
3
) were isolated from Hif1a DF; 
PyMT+ females. Tumors were chopped with scalpels then with razor blades and the paste 
digested with type III collagenase (1 mg/ml, Worthington Biochemical, Lakewood, NJ) 
in RPMI media containing 5% FBS (5 ml/g tissue) for 2 hours at 37°C. Cells were 
pelleted at 1100 rpm and then washed 4 times with digestion buffer. Cells were plated 
with F12 medium containing 5 ?g/ml insulin, 2 ?g/ml hydrocortisone, 5 ng/ml EGF,     
50 ?g/ml gentamycin, 100 U penicillin/streptomycin and 10% FCS, as described by 
Rijnkels, M., et al. [88]. After 48-72 h, the plating medium was switched to complete 
mammary cell growth medium (DMEM/F12, 5% FBS, 5 mg/ml insulin, 10 ng/ml EGF). 
A subset of MTECs was subsequently weaned to reduced growth factor media 
(DMEM/F12 + 2% FBS or DMEM/F12 + 0.5% FBS). For sub-cultivation, cells were 
rinsed twice with Puck's A saline, then incubated for up to 60 min at 37°C in a 3:1 
solution of dispase II/0.025% trypsin reconstituted in Puck's A saline. No EDTA was 
utilized for subcultivating cells, as we found that treating cells with trypsin-EDTA 
changed tumor cell morphology from an epithelial (cuboidal) to a mesenchymal (spindle) 
appearance. The luciferase expressing MTEC cells were generated by transducing 
monolayer cultured WT cells with pEILP (eIF1alpha-Luciferase2-IRES-puromycin, 
Junming Yue, UTHSC Viral Vector Core) lentivirus particles at 10 m.o.i. For 48 h hours, 
followed by washing and immediate selection with puromycin to establish pools of stable 
transfectants. All cells were passaged fewer than 30 times and media was routinely tested 
for mycoplasma using the MycoAlert kit (Lonza, Basel, Switzerland).   
 
 
Animals 
 
 All animal studies were performed in accordance with the guidelines established 
by the Animal Care and Use Committee at The University of Tennessee Health Science 
Center.  Fifty-six 8-week-old female FVB mice were intravenously injected with 
luc-MTECs (1x10
6
 cells) resuspended in 100 ?l of sterile PBS containing 0.9 mM CaCl2 
and 0.493 mM MgCl2. The injected animals were then divided into two groups. Group I 
contained 30 mice and group II contained 26 mice.  
                                                
 
1
 Manuscript in preparation: Schawb, L., Peacock, D., Cushing, R., Majumdar, D., Ingels, 
J. and Seagroves, T., Hypoxia Inducible Factor-1a Promotes Primary Tumor Growth and 
Tumor-Initiating Cell Activity in the MMTV-PyMT Model of Breast Cancer. 
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 Group 1. To determine the effect of AM9D treatment on early stage of 
metastasis, mice in this group were divided into 3 sub-groups of 10 mice each. On day 
1-post MTEC injections the mice received weekly injections of PBS (100 ?l; subgroup 
1a), AM9D (1500 ?g/100 ?l PBS; subgroup 1b) or control DNAzyme (1500 ?g/100 ?l 
PBS; subgroup 1c). All animals were anesthetized with isoflurane before each injection. 
Mice received a total of 3 treatments on days 1, 7, and 14 post tumor cells injections and 
were euthanized one week after the last DNAzyme treatment (Day 21). Mice were 
weighed weekly and observed for any signs of lethargy (i.e. weight loss, trouble 
breathing, not grooming) during treatment. Xenogen Bio-imager was used to monitor the 
development of lung nodules on days 14 and 21 post tumor cell inoculation. The 
luciferase positive cells were identified in lungs on day 21-post tumor inoculation at 
which time treatments were stopped and animals were sacrificed. Their lungs were 
inflated with 4% paraformaldehyde by cannulation of the trachea, excised, and 
photographed for any visual macro metastasis. Lungs were then fixed in 4% 
paraformaldehyde overnight. Paraffin embedded, 4 micron frozen sections were prepared 
and analyzed by Dr. Stanley Kosanke (Pathologist, University of Oklahoma). The lung 
sections were analyzed for the presence of macro and micro lung metastasis. At necropsy, 
liver, heart, brain, kidney, and spleen were collected and fixed in 4% paraformaldehyde, 
impregnated with 25% sucrose that acts as a cryoprotectant, and were processed for 
histopathological evaluation (standard light microscopic examination of hematoxylin and 
eosin-stained tissue slides). 
 
 Group 2. To determine the effect of AM9D treatment on survival of the animals 
with lung nodules, the MTEC inoculated mice were divided into 3 subgroups of 8-9 mice 
each. The mice in this group received weekly injections of PBS (100 ?l; subgroup 2a; 
n=8), AM9D (1500 ?g/100 ?l PBS; subgroup 2b; n=9) or control DNAzyme (1500 
?g/100 ?l PBS; subgroup 2c; n=9) starting from the first day post MTEC injection. Mice 
were weighed weekly and monitored for any signs of lethargy (i.e. weight loss, trouble 
breathing, not grooming). The animals were then sacrificed when they lost ~20% body 
weight, or if they had trouble breathing, were panting and not grooming. The maximum 
treatment received by the last surviving animals was 9 injections and these animals were 
euthanized one week after the last treatment. Lungs were excised, photographed, weighed 
and fixed in 4% paraformaldehyde, as stated above. 
 
 
RESULTS AND DISCUSSION 
 
 
Effect of AM9D Treatment on Early Stage Experimental Metastasis 
  
 The efficacy of AM9D treatment in inhibiting and/or reducing early stage 
experimental metastasis was tested by treating luciferase labeled MTEC (luc-MTEC) 
inoculated FVB mice with PBS, 1500 ?g of either AM9D or control DNAzyme, once a 
week for three weeks. The animals were monitored weekly for the presence of luc-MTEC 
in lung by Xenogen. At the earliest detection of MTEC in the lung (twenty one days after 
the initial treatment), animals were sacrificed. Luc-MTEC injected via tail vein of the 
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animals were able to metastasize to and colonize in the lungs (Figure 4-1). The average 
number of gross macro metastases observed in AM9D (1.1 ± 1.5) and control DNAzyme 
treated animals (1.6 ± 3) were, however lower than that of PBS treated groups  
(20.25 ± 31.3; Figure 4-2). This data suggests that AM9D and control DNAzyme 
treatment were equally effective in inhibiting metastasis and lung colonization. However, 
we cannot ignore the large standard deviation in the PBS control cohort due to the 
variability of 0 to more than 70 surface nodules observed at this stage of experimental 
metastasis. The analysis of macro metastasis in sectioned lung tissue revealed that AM9D 
therapy retarded lung metastasis by 56% compared to PBS, however, control DNAzyme 
treatment was 72% and 88% more effective in reducing lung macro metastasis than both 
AM9D and PBS treatments, respectively (Figure 4-2b).  
 
 The analysis of micro metastasis in sectioned lung tissues also revealed that 
control DNAzyme therapy retarded lung micro metastasis by 34% and 24% compared to 
AM9D and PBS treatment, respectively (Figure 4-2c). As mentioned above, a few mice 
in each group did not show any signs of gross macro metastasis (Figure 4-1a). However, 
analysis of lung tissue slices revealed that majority of the animals developed lung 
nodules, irrespective of lack of gross lung macro metastasis. The percentages of control 
DNAzyme, AM9D, and PBS treated animals that did not show any gross macro 
metastasis were 57%, 50%, and 37%, respectively. These data suggest that AM9D and 
control DNAzyme therapy are equally affective in reducing lung metastasis. These data 
also suggest that although AM9D down-regulates MMP-9 protein production in vitro and 
in vivo, both AM9D and control DNAzyme may have a sequence-related off target effect.  
 
 Bacterial DNA containing unmethylated CpG dideoxynucleotide sequence motifs 
have been shown to stimulate immune cells and this stimulatory effect can be mimicked 
 
 
 
 
 
Figure 4-1. Representative lungs images extracted from two mice in the PBS 
treated group at early stage experimental metastasis. 
 
PBS treated mice had  (a) as few as no macromets to (b) greater than 70 macromets as 
visualized by gross tissue analysis. Arrows in (b) are pointing to macromets. 
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Figure 4-2. Macro and micro metastasis in lungs from early stage experimental 
metastasis. 
 
Luc-MTEC inoculated Mice were treated weekly with PBS or 1500 ?g of either AM9D 
or control DNAzyme for 3 weeks and their lungs were analyzed grossly for (a) macro 
metastasis (p=0.092) and a section from each lung were analyzed for (b) macro 
metastasis (p=0.146) and (c) micro metastasis (p=0.538).  
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by synthetic CpG containing oligodeoxynucleotide (CpG-ODN) [89]. CpG motifs have 
been shown in literature to activate Toll-like receptor 9 (TLR9) and lead to the activation 
of macrophages, dendritic cells, and B cells [89, 90]. This activation is important for the 
treatment of cancer. CpG monotherapy is sufficient for inducing T-cell-mediated 
rejection of established tumors [91]. For these reasons, synthetic CpG-ODNs are 
currently in human clinical trials for the treatment of cancer [89]. In addition, CpG’s that 
contain a purine two bases ahead of or a pyrimidine two bases after the CG nucleotides 
have been shown to be more stimulatory compared to CpG-ODNs that do not [90]. The 
sequences of AM9D and the control DNAzyme each contain two CpG motifs making 
them possible functional CpG-ODNs (Figure 4-3). The presence of macrophages and 
dendritic cells in lungs of animals treated with AM9D and control DNAzyme should 
attest to this hypothesis. Macrophages and dendritic cells were not observed in lungs 7 
days after injection, however, lungs should be observed at a shorter time after injection. 
 
 AM9D was well tolerated in this early stage experimental metastasis mouse 
model. Body weights of animals in all groups were similar throughout the 3 weeks of 
treatment and at sacrifice (Figure 4-4). No obvious adverse effects, including swelling of 
joints and difficulty in walking, were observed in DNAzyme-treated mice. Furthermore, 
analysis of organs from mice exposed to weekly injections of AM9D or control 
DNAzyme for 10 weeks showed no toxic effects (Figure 4-5). 
 
 
Effect of Long Term AM9D Treatment on Lung Tumor Load in Experimental 
Metastasis and on Survival 
 
 The efficacy of long term AM9D therapy to reduce lung tumor load and increase 
survival was tested by intravenously injecting PBS or 1500 ?g of AM9D or control 
DNAzyme into 8 week old female FVB mice previously injected with 1x10
6
 luc-MTECs, 
once a week until mice showed signs of lethargy (~20% weight loss, trouble 
breathing/panting, and/or not grooming). The animals were then sacrificed; their lungs 
were excised, weighed, and photographed. Mice were observed bi-weekly to determine 
changes in health and weighed weekly (Figure 4-6a). The lungs of all animals sacrificed 
due illness were completely covered with macro metastasis and no differences between 
the wet weight of lungs extracted from AM9D and control treated animals was observed 
(Figure 4-6b). Lungs in the PBS treated cohort showed a slightly elevated lung tumor 
burden (calculated by dividing lung weight by body weight; Figure 4-6c) compared to 
control DNAzyme and AM9D treated mice. Mice in the AM9D treated group displayed 
increased signs of progression-free survival between analysis points 34 to 42 days, 
however there was no significant extended survival compared to the control treated 
groups (log rank test, p>0.05; Figure 4-7). This data is consistent with the results 
obtained from Marimastat clinical trial studies demonstrating that progression-free 
survival significantly increased in the patients with inoperable gastric cancer using 
Marimastat, but overall survival did not improve. In subgroups of patients with prior 
chemotherapy and of patients without distant metastases, overall survival was 
significantly better in the Marimastat-treated group [45]. These data suggest that AM9D 
 
41 
 
 
 
Figure 4-3. CpG regions in AM9D and control DNAzyme. 
 
AM9D and control DNAzyme both contain two CpG regions (red). In each of these 
sequences one of the CpG regions has a pyrimidine 2 spaces after (orange). In the AM9D 
sequence there is a purine 2 spaces before the CpG region (blue). 
 
 
 
 
 
 
Figure 4-4. Mouse body weights measured during experimental metastasis 
 
The body weights of all the experimental animals were maintained during the course of 
the treatment (3 weeks) and no difference in body weights was observed between PBS 
(green), AM9D (blue) or control DNAzyme (red) treatment groups.  
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Figure 4-5. Analysis of mice organ pathology. 
 
Mice intravenously injected with luc-MTEC and treated with once weekly injections of 
1500 ?g of either AM9D or control DNAzyme showed no difference in organ pathology. 
Representative images of various organs of AM9D and control DNAzyme treated mice 
shown (400x magnification).   
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Figure 4-6. Effect of various treatments on mice lung tumor burden.  
 
(a) Mice treated with once weekly injections of PBS or 1500 ?g of either AM9D or 
control DNAzyme were weighed on their final day of survival.   Mice lungs were 
weighed upon excision (b) and their total lung tumor burden (c) was calculated. Weights 
of mice and lungs and calculation of lung tumor burden did not show a significant 
difference between AM9D, control DNAzyme, and PBS treated groups (p>0.05; error 
bars show standard deviation). 
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Figure 4-7. Survival curve. 
 
Survival curve of mice injected with 1x10
6  
luc-MTEC and treated with weekly injections 
of 100 ?l PBS (green), 1500 ?g AM9D (blue) or control DNAzyme (red). Log Rank Test 
p=0.5. 
 
  
can be used as an adjuvant to primary surgery in order to blunt tumor growth and treat 
metastasis. 
 
 The lack of effect of long term AM9D treatment on tumor growth and overall 
survival in this experimental metastasis model may be due to time of AM9D delivery, 
frequency of delivery, mouse strain, pro-tumorigenic effects of MMP-9 downregulation, 
or a combination of these effects.  
 
 Time of delivery and/or frequency of delivery of AM9D may be responsible for 
the lack of significant decreased tumor burden in AM9D treated mice compared to 
control cohorts. Shibue, et al., have shown that D2 cells extravasate into lungs between 
3-48 h after tail vein injection [92]. If MMTV-PyMT MTECs mimic this behavior, 
DNAzyme treatment may have been administered too late to block extravasation and 
colonization. Chen, et al., showed that treatment of CT26 (colon carcinoma cells) 
inoculated mice with 40 mg/kg/day of doxycyclin starting immediately or 2-weeks after 
tumor cell injections resulted in fewer but larger and more vascularized lung tumors. On 
the other hand, when therapy started at the time of tumor injections, mice had fewer lung 
tumors than mice treated 2-weeks after injection of colon carcinoma cells [83]. This 
suggests that the time and/or the frequency of the treatment have significant effect on 
development of lung experimental metastasis. In both early stage metastasis and long 
term AM9D treatment experimental groups, DNAzyme treatment began one day after 
injection of MTEC tumor cells and continued once weekly. The data presented in  
Chapter 3 (Distribution, Clearance, and Cytotoxicity of DNAzyme) indicated that 
DNAzyme administrated intravenously is cleared from the lung within 24 h, but has an 
extended clearance from mammary tumors. Therefore, while weekly intratumoral 
injections may have been effective in reducing tumor growth (Figure 2-4), it may not be 
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sufficient for treatment of lung metastasis. If the observed lack of significant effect of 
AM9D therapy on survival of animals with lung metastasis is due to time of initial 
treatment or frequency of drug delivery, future experiments with DNAzyme treatment 
should begin in advance to or at the same time as tumor cell inoculations and delivered 
more frequently. We have observed, however that bi weekly injections (100 ?l/injection), 
via tail vein results in hardening of the tail and necrosis. Therefore, the use of a different 
avenue of DNAzyme delivery is a necessity. Jugular vein may be the most efficient route 
for delivery of AM9D. This would allow for daily administration of 75 mg/kg AM9D, 
which would result in a total delivery of 525 mg DNAzyme/kg/week.  
 
 As mentioned above, Chen, et al., showed that intravenous administration of      
40 mg/kg/day of doxycyclin into animals inoculated with CT26 (colon carcinoma cells) 
immediately or 2-weeks after tumor cell injections resulted in fewer but larger and more 
vascularized lung tumors. The increased vascularization was attributed to decreased 
production of angiostatin by MMP-9 [83]. Thus, MMP-9 inhibitors may have a null or 
pro-tumorigenic effect when administered intravenously. If anti-MMP-9 DNAzyme 
(AM9D) therapy leads to (1) decreased MMP-9 protein, (2) decreased anti-angiogenic 
factors, and (3) subsequent increased vascularization, then it is expected that AM9D 
treated animals develop larger lung tumors and have a decreased survival rate than the 
control DNAzyme and PBS treated cohorts. This is contrary to our observation that the 
AM9D treated mice showed increased signs of progression-free survival between 
analysis points 34 to 42 days compared to control cohorts (Figure 4-7). Hence, while 
AM9D did not show extended survival compared to control treated animals, it also did 
not show detrimental effects such as larger tumors or decreased survival. Thereby, the 
therapeutic effect of AM9D on experimental metastasis should continue to be evaluated 
with several adjustments in treatment regimen. 
 
 Another possibility for the observed lack of significant outcome of AM9D 
therapy on lung experimental metastasis may be related to the mouse strain used in these 
studies.  Martin et al. showed that the treatment outcome of a gelatinase inhibitor, 
SB-3CT, on experimental metastasis is strain dependent [68]. In their experiments, 
luciferase-labeled 17L3C cells (MTEC from MMTV-PyMT mice) were injected via tail 
vein into C57BL/6 and FVB/N mice followed by daily injections of 50 mg/kg of the drug 
SB-3CT or vehicle for 14 days. They found that SB-3CT therapy resulted in a significant 
decrease in tumor growth in C57BL/6 mice, while mice on a FVB/N background showed 
enhanced tumor growth according to luciferase signal upon treatment. The mice utilized 
in our experimental metastasis model are FVB/N, the same strain that showed enhanced 
tumor growth when treated with a gelatinase inhibitor in the Martin, et al. publication 
[68]. These data suggest that the mice with different genetic backgrounds should be used 
to assess the significance of genetics on efficacy of AM9D in experimental metastasis.  
 
 In Chapter 2, I have shown that AM9D is able to reduce tumor growth by up to 
50%. In order to determine if AM9D can be used in the treatment of breast cancer 
metastasis, the determining factor in breast cancer patient survival, the aforementioned 
experiments (including changes in time and frequency of treatment) must be performed.   
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CHAPTER 5.     MMP-9 TRESSPASSES ON MMP-1’S TURF 
 
 
INTRODUCTION 
 
 High expression levels of a variety of Matrix Metalloproteinases (MMPs), 
including MMP-1 and MMP-9 have been reported to be associated with progression and 
poor prognosis of breast cancer [93-95]. MMP-1 and -9 degrade type I and type IV 
collagen, respectively, two of the most abundant collagens in the ECM [11], making both 
enzymes important in cancer development, proliferation, and angiogenesis through their 
involvement in ECM degradation and cytokine release and activation [10, 11]. With the 
use of a transgenic multistage carcinogenic mouse model, MMP-9 has been shown to be 
up regulated in angiogenic islets, leading to an increase in the bioavailability of VEGF 
[30]. MMP-1 has been shown to be one of the most highly over expressed genes in bone 
metastasis [7]. In addition, researchers have shown that the presence of MMP-1 in the 
stromal-tumor microenvironment plays a role in altering the behavior of tumor cells by 
binding to and activating PAR1 and facilitating invasion [5, 96]. We have shown that 
down regulation of MMP-9 by AM9D inhibits the invasion of MDA-MB-231 cells 
(Chapter 1, Figure 1-3d). Thus, inhibition of MMP-1 and -9 expression can be used as a 
therapeutic modality to decrease growth and invasion of tumor cells. 
   
 Although MMP-1 and -9 have different substrate specificity, they are both 
composed of three major domains: NH2-terminal pro-domain, central catalytic domain, 
and COOH-terminal hemopexin-like domain connected to catalytic domain via a 
proline-rich hinge region (Figures 1-1 and 5-1). The hinge region of MMP-9 is extended 
and is similar to Type V collagen. During protein activation, the pro-domain is cleaved 
[97]. MMP-9 has an additional domain known as the gelatin binding domain composed 
of 3 homology fibronectin-type II modules of 58 amino acids inserted into the catalytic 
domain (Figure 5-1b) [98]. We have shown that this domain is responsible for the type V 
collagen activity of the enzyme [40, 99]. The carboxyl-terminal domain of MMP-9 is 
involved in anchoring the enzyme to CD44 [100-102] and binds to heparin [103]. 
Although, the role and significance of individual domains in substrate recognition by 
MMP-9 has been defined, the enzyme reaction mechanism of MMP-9 has yet to be 
determined. 
 
 Latent MMP-9 is a 92 kDa protein that upon activation is converted to an 82 kDa 
protein that auto-catalytically process to a 68 kDa (fully processed) species [104]. Many 
cell lines studied contain both 82 kDa and 68 kDa proteins [102, 104]. In an attempt to 
delineate the complete role of MMP-9 in breast cancer, we isolated and purified the 92 
kDa latent MMP-9 from a highly invasive human breast cancer cell line, MDA-MB-231 
and demonstrated that it can be fully processed to a 68 kDa protein upon activation.  The 
amino terminal amino acid analysis of the 68 kDa protein revealed that it has the same 
NH3-termini, Met
75
, as the 82 kDa protein, indicating that 68 kDa protein is a carboxyl 
terminal truncated form of the enzyme. Further characterization of the 68 kDa protein 
revealed that the enzyme in addition to gelatin and types V and XI collagens, similar to 
MMP-1, was also able to cleave native triple helical type I collagen. As mentioned  
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Figure 5-1. Schematic diagram of MMP-1 and -9. 
The enzymes share pro-domain (grey), a catalytic domain (yellow and red), a hinge 
region domain (black jagged line), and a c-terminal hemopexin-like domain (dark blue). 
The catalytic domain of all MMPs contain a Zn binding active site (AS) region (red). The 
hinge region domain is located between the catalytic and c-terminal hemopexin-like 
domain (a and b). MMP-9 contains an extended hinge region, which is often referred to 
as the type V collagen-like domain (blue oval) due to its Proline rich composition. The 
catalytic domain of MMP-9 contains 3 homology fibronectin-like repeats, shown in light 
green (b).  
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previously, the 82 kDa protein does not cleave type I collagen as a substrate. These data 
suggest that MMP-9 plays a dual role in tumor cell invasion; by cleaving type IV 
collagen, it exposes an HUIV26 cryptic site that is important for angiogenesis and tumor 
growth [31] and by cleaving type I collagen, the most abundant collagen of the ECM it 
aids MMP-1 in increasing the proliferation and invasive potential of tumor cells. This 
dual role that MMP-9 plays in tumorigenesis makes it an even more attractive anti-cancer 
target. To derive a therapeutic efficient inhibitor specific for MMP-9, it is important to 
investigate MMP-9 mechanism of substrate specificity.  
 
 In this Chapter, the mechanism of type I collagenolysis of 68 kDa MMP-9 was 
investigated by deletion and alanine scanning site directed mutagenesis techniques.  
These studies revealed that presence or the lack of interaction between the side chains of 
Glu
415
 in the active site and Glu
447
 and/or Arg
451
 located in the hinge region determines 
specificity of MMP-9 toward type I collagen substrate. The carboxyl-terminal truncated 
68 kDa species lacks both Glu
447
 and Arg
451
 thus, its active site
 
is flexible and capable of 
accommodating and consequently cleaving type I collagen. On the other hand, the 
interaction between Glu
415
 and Glu
447
 and/or Arg
451
 makes the active site of 82 kDa 
MMP-9 rigid, preventing the enzyme from cleaving type I collagen as a substrate.  
 
 
MATERIALS AND METHODS 
 
 
Mutagenesis 
 
 MMP-9 ?444-502. Type-V like hinge domain (amino acid residues 444-502) was 
deleted from the full-length MMP-9 cDNA (pETNG) by the polymerase chain reaction 
(PCR) procedure. The pETNG expression system containing full length MMP-9 cDNA 
[75] was used as a template for two separate PCR reactions. The 5’ primer, 5’-AAG 
GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ and 3’ primer, 
5’-GG CAC AGT AGT GGC ACC ATA GAG GTG CCG GAT GCC-3’ were used to 
amplify a 1.55kb region of the pETNG corresponding to nucleotides 43 to 1593 and the 
5’ primer , 5’-GGC ATC CGG CAC CTC TAT GGT / GCC ACT ACT GTG CC-3’ and 
3’ primer , 5’-TCG AGG TCG ACG GTA TCG ATA AGC TTG ATA TCG AAT-3’ 
were used to generate a ~0.85 kb PCR product corresponding to nucleotides 1381  to 
2400 (1401-1575 looped out) of the MMP-9 sequence.  The PCR products were 
sequenced to verify that the desired deletion mutation is the only mutation generated by 
PCR.  The 1.55 kb and 0.85 kb PCR products were used to generate 2.3 kb MMP-9 
cDNA lacking Type-V like hinge domain (nucleotides 1401-1575) by PCR using 
5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ and, 
5’-TCG AGG TCG ACG GTA TCG ATA AGC TTG ATA TCG AAT-3’ as 5’ and 3’ 
primers, respectively.  The 2.3 kb PCR product was digested with restriction enzymes 
XbaI and SalI and the 2.2 kb XbaI/SalI cDNA fragment was ligated to NheI/SalI 
fragment of the expression vector pET12C for 1 h at room temperature using T4 DNA 
Ligase (Promega, Madison, WI) to generate pET?444-502.  
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 Alanine Scanning Site-Directed Mutations in ?CT(1-456). The following 3’ 
mutagenic primers were used to substitute Arg
445 
(nucleotides 1405-07), Glu
447
 
(nucleotides 1411-13), Glu
449
 (nucleotides 1417-19) or Arg
451 
(nucleotides 1423-25) with 
Ala (substituted nucleotide(s) underlined)  and generate a stop codon at position 446 
(nucleotide 1439) in MMP-9 molecule using pETNG as template: R445A, 5’-GAC TCT 
AGA CTA TTA GGT GGT GGT TGG AGG CCG TGG CTC AGG TTC AGG GGC 
AGG ACC ATA-3’; E447A, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT 
TGG AGG CCG TGG CTC AGG TGC AGG GCG AGG-3’; E449A, 5’-CAG GTC 
GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG CCG TGG CGC AGG TTC 
AGG-3’; R451A, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG 
CGC TGG CTC AGG-3’. All of the above primers were complimentary to nucleotides 
1401-1439 in NG and contained a unique XbaI restriction site (TCT AGA) and a STOP 
codon (TAG) at the 3’end. The 5’ primer used in all of the above PCR reactions was 
5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’. All the 
PCR products were sequenced by Dideoxy method [99] and were found to be free of any 
secondary mutations. The resulting PCR products were digested with XbaI and SalI and 
ligated to NheI /SalI fragment of pET-12C expression vector. 
 
 E415G in ?CT(1-456). This mutant was generated using two PCR reactions and 
pETNG as a template. The first PCR used 5’ primer, 5’-CAT TCC TCA GTG CCG GGG 
GCG CTC ATG TAC CC-3’ and 3’ primer, 5’-CAG GTC GAC TCT AGA CTA TTA 
GGT GGT GGT TGG AGG-3’ to generate a 160 bp PCR fragment containing 
nucleotides 1300 to 1440. The above 5’ primer contained a unique XbaI restriction site 
(TCT AGA) and a STOP codon (TAG) at the 3’end. This 160bp fragment was used as a 
3’primer for the second round of PCR using pETNG as a template and 5’-AAG GAG 
ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ as 5’ primer. This 
generated a 1.4 kb PCR product (nucleotides 43-1440), which was digested with 
restriction enzymes NdeI and XbaI and ligated to NdeI-NheI fragment of pET-12c 
expression vector as described above. 
  
 Double Mutant. The ?CT(1-456)  E415G/E447A mutant was generated using the 
previously published Gel. B/E415G mutant in pET-12c as a template [105]. The 5’ 
primer, 5’-AAG GAG ATA TAC ATA TGC GGG CGA AAC TCC TAG GAA TAG-3’ 
and 3’ primer, 5’-CAG GTC GAC TCT AGA CTA TTA GGT GGT GGT TGG AGG 
CCG TGG CTC AGG TGC AGG GCG AGG-3’, were used to generate Glu to Ala 
mutation at position 447  (nucleotides 1341-1343) and a stop codon at position 456 
(nucleotide 1439) in MMP-9 E415G mutant protein resulting in ?CT(1-456) truncated 
mutant with Glu
415
 to Gly and Glu
447
 to Ala substitutions. The PCR product was digested 
with XbaI and SalI and ligated with NheI and SalI fragment of pET-12c expression 
vector (Novagen, Rockland, MA). 
  
 Enzyme Purification. Plasmids encoding for wild-type and mutant enzymes were 
introduced into E. coli strain BL21(DE3)(pLysS), the cells bearing the plasmids were 
induced by IPTG and the latent recombinant proteins were purified on gelatin-agarose 
affinity columns as described previously [75]. Purified enzymes were dialyzed against 
50 
50mM Tris-HCl, pH 7.5, 5mM CaCl2, 150mM NaCl, and 2mM ZnCl2 and stored at    
-20 ˚C until use.  
 
 
Gelatin Zymography 
 
 The activity of the purified enzymes toward gelatin was assessed by running 
proteins on a non-reducing SDS/Polyacrylamide gel (8%) containing 1 mg/ml gelatin. 
Protein samples were mixed with the SDS/PAGE sample buffer without reducing agents 
and were loaded without being boiled. After electrophoresis, the gels were washed twice 
with 50 mM Tris-HCl, 5 mM CaCl2, 1 mM ZnCl2, 1% Triton X-100, and 0.02% NaN3 
at 25 ˚C and incubated in the same buffer for 16 h at 37 ˚C. The gels were stained with 
Coomassie Brilliant Blue. Gelatin zymography depicts MMPs as negatively stained 
bands of gelatinolytic activity.  
 
 
Determination of Kcat/Km Values for the Fluorogenic Peptide Substrate 
Mca-PLGL(Dpa)AR-NH2.  
 
 The latent enzymes were activated by 1 mM APMA at 37ºC for 14-16 h. The 
concentrations of the active enzymes, [E]T, were determined by active-site titration with 
the MMP inhibitor GM6001 as described previously [106]. The Kcat/Km values for the 
fluorogenic peptide substrate were then obtained by assaying the enzymes at 23ºC using 
1.5 ?M peptide substrate as previously described [99]. Assays were conducted under the 
condition where Km >> [S], and Kcat /Km values were calculated from the following 
equation: Kcat /Km = vo / [E]T[S].   
 
 
Kinetic Analysis of Type I Collagenolytic Activity  
 
 To determine the Kcat/Km values of the MMP-9 mutant enzymes for type I 
collagen, enzymes (0.02 ?M) were mixed with various concentrations of bovine type I 
collagen (1.1, 1.65, 2.2, and 2.75 μM) in assay buffer that was composed of 50 mM Tris, 
pH 7.5, 5 mM CaCl2, 150 mM NaCl, and 2 μM ZnCl2. Reactions were allowed to 
proceed at 27 °C for 6 h before being quenched by the presence of 10 mM EDTA. 
Reaction mixtures were boiled for 5 min and electrophoresed on 8% SDS-PAGE. 
Proteins bands were visualized by Coomassie Brilliant Blue staining. The integrated 
intensities of the ?1(I) and ?2(I) collagen bands were determined by using an Alpha 
Imager 2000 documentation and analysis system (Alpha Innotech Corp., San Leandro, 
CA). The difference between the integrated intensities of the ?1(I) collagen band in the 
presence and in the absence of the enzyme was used to calculate the catalytic activity of 
the enzyme as described previously [107].  
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Analysis of Gelatinolytic Activity of the Enzymes 
 
 The gelatinolytic activity of enzymes was determined using 
14
C-labeled gelatin as 
described previously [40, 108, 109]. Specific activity was calculated by dividing the 
amount of gelatin degraded per hour by the nanomoles of enzyme present in the assay. 
The assays were performed in triplicates and the results were averaged. 
 
 
RESULTS 
 
 
Expression, Purification, and Activation of Deletion Mutant Enzymes 
 
 The major aim of this study was to identify the structural elements that are 
sufficient to endow MMP-9 with type I collagenolytic activity. Since the fully processed 
carboxyl-terminal truncated MMP-9 (68 kDa protein) was shown to be able to cleave 
type I collagen, a series of MMP-9 deletion mutant enzymes (Figure 5-2) were designed 
to address the role and significance of the hemopexin domain and hinge region in type I 
collagen substrate specificity of MMP-9. The first deletion mutant, ?CT(1-456) consisted of 
complete deletion of the hemopexin domain (amino acid 503-706) and partial deletion of 
the hinge region (amino acid 457-502). ?CT(1-443) consisted of complete deletion of both 
the hemopexin domain and the hinge region (amino acids 444-706).  The ?444-502 
mutant is comprised of MMP-9 molecule lacking only the hinge region, amino acid 
residues 444-502.  All mutant enzymes were expressed in E. coli as latent enzymes and 
purified on gelatin agarose affinity column as described previously [75].  
 
 
Characterization of Deletion Mutants MMP-9 
 
 To assess whether deletion mutants were correctly folded and retained general 
proteolytic activity, they were activated with APMA and the catalytic efficiencies of 
MMP-9, ?CT(1-456), ?CT(1-443) and MMP-9 ?444-502 enzymes toward gelatin and a 
general MMP fluorogenic peptide substrate, Mca-PLGL(Dpa)AR-NH2, were determined.  
As demonstrated in Figure 5-3 and Table 5-1, all activated mutant enzymes were able to 
cleave gelatin. However, only the ?444-502 mutant enzyme with intact hemopexin 
domain had similar gelatinolytic activity as the wild type MMP-9. All other deletion 
mutations resulted in a decreased catalytic efficiency of the enzyme toward  
gelatin substrate. ?CT(1-456) and ?CT(1-443) mutants had 3.2-fold and 3.6-fold lower 
activity toward gelatin compared to WT MMP-9, respectively (Table 5-1). This is  
consistent with Roeb, et al., finding that MMP-9 hemopexin domain has a high affinity 
for gelatin [103]. Therefore it is not surprising that ?CT(1-443) and ?CT(1-456), both lacking  
the hemopexin domain, had lower activity toward gelatin substrate while, specific 
activity of MMP-9 hinge region deleted mutant (?444-502) for gelatin was similar to that 
of the wild type enzyme.  
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Figure 5-2. MMP-9 recombinant deletion mutants. 
 
Full-length MMP-9 is comprised of 706 amino acids and does not use type I collagen as a 
substrate. ?444-502 mutant is comprised of MMP-9 molecule lacking hinge region, 
amino acid residues 444-502. ?CT(1-456) recombinant mutant lacks amino acid residues 
457-706 corresponding to the hemopexin domain and partial hinge region. In ?CT(1-443) 
recombinant mutant both hemopexin domain and hinge region were deleted (amino acid 
residues 444-706). 
 
 
 
 
 
 
 
 
 
53 
 
 
 
Figure 5-3. Gelatin- gel zymography of purified mutant enzymes.  
 
(a) Lanes 1, 3, and 5 show the latent form of WT MMP-9, ?CT(1-456) and ?CT(1-443), 
respectively. Lanes 2, 4, and 6 shows the active form of WT MMP-9, ?CT(1-456) and 
?CT(1-443), respectively. (b) Lanes 1 and 2 show the latent and active forms of ?444-502, 
respectively.  
  
 
Table 5-1. Proteolytic activity of deletion mutant enzymes  
 
Enzyme 
?M-1 
Kcat/Km 
(McaPLGLDpaAR) 
mM
-1
S
-1
 
Specific Activity 
for Gelatin 
?g/h/nmol 
Kcat 
Type I 
collagen 
Km 
Type I 
collagen 
Kcat/Km 
Type I 
collagen 
   h
-1
 ?M-1 h-1 ?M-1 
MMP-1 14.17 ± 0.5 272 ± 9 146 5.36 27.23 
MMP-9 585 ± 30.9 187,669± 11,921 ND ND ND 
?444-502 145.33 ± 2.58 187,157 ± 224 33.03 8.9 3.71 
?CT(1-456) 128.9 ± 14.1 58,959  ± 359 ND ND ND 
?CT(1-443) 613 ± 2.1 52,272 ± 5149 3.7 2.1 1.8 
      
ND=Not Determined 
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 As shown in Table 5-1, the catalytic efficiency (Kcat/Km) of both ?CT(1-456) and 
?444-502 toward the Mca-PLGL(Dpa)AR-NH2 were 4.5 and 4 times lower than that of 
the wild type enzyme, respectively. The ?CT(1-443) mutant, however, had similar Kcat/Km 
for the peptide substrate to wild type MMP-9 (585 ± 30.9 mM
-1 
S
-1
). These findings 
suggest that presence of amino acid residues 444-456 in the hinge region plays a role in 
general proteolytic activity of the enzyme. 
 
 As mentioned previously, contrary to 82 kDa MMP-9, the 68 kDa active MMP-9 
cleaves type I collagen, suggesting a role for carboxyl terminal domain and hinge region 
in type I collagenolytic activity of the enzyme. Therefore, the ability of deletion mutants 
to cleave type I collagen was assessed. As demonstrated in Table 5-1, only deletion 
mutants lacking the entire hinge region with (?444-502) or without (?CT(1-443)) the 
carboxyl terminal domain were able to cleave type I collagen. ?CT(1-443), in addition to 
gelatin and type V collagen (data not shown), was able to use triple helical type I 
collagen as a substrate (Table 5-1) with Kcat/Km value of 1.8 h
-1 ?M-1. This value is 15.1 
times lower than the value obtained for MMP-1 (27.23 h
-1 ?M-1). Interestingly, contrary 
to this enzyme, ?CT(1-456) does not cleave type I collagen, suggesting that presence of 
amino acids 444-456 in the ?CT(1-456) molecule hinders the enzyme from utilizing type I 
collagen as a substrate. This hypothesis was confirmed by the observation that complete 
deletion of the hinge region from the full length MMP-9 (?444-502) endowed the 
enzyme with type I collagenolytic activity. The catalytic efficiency of the ?444-502 
mutant toward type I collagen substrate was 3.71 h
-1 ?M-1 (Table 5-1).  This values is 2 
times higher than the value obtained for ?CT(1-443).  This may be due to the hemopexin 
domain binding to and helping to present type I collagen to the AS in ?444-502 
molecule.  
 
 
Glu
447
 and Arg
451
 Residues in the Hinge Region Play a Role in Type I Collagenolytic 
Activity of MMP-9  
 
 Analysis of activity of ?CT(1-456) and ?CT(1-443) enzymes toward type I collagen 
substrate suggested that the 13 amino acid residues, 
444
PRPEPEPRPPTTT
456 
in the hinge 
region of MMP-9  determines the substrate specificity of the enzyme (Figure 5-4,  
Table 5-2). The role of specific amino acid residues in this region of the MMP-9 
molecule in its type I collagenolytic activity was evaluated by alanine scanning site 
directed mutagenesis. The charged amino acid residues, Arg
445
, Glu
447
, Glu
449
 and Arg
451
 
in ?CT(1-456) (Figure 5-4) were individually substituted with Ala and the effect of each 
mutation on substrate specificity of the enzyme was evaluated.  All site directed mutant 
enzymes were expressed in E. coli, purified, and their enzymatic activities were 
determined following activation by APMA.  
 
 Gelatin gel zymography showed that upon activation with APMA, the 45 kDa 
unglycosylated latent R445A, E447A, E449A, and R451A ?CT(1-456) mutant enzymes 
were converted to 37 kDa active species (Figure 5-5) as expected. 
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Figure 5-4. Alanine mutations in ?CT(1-456).  
 
Schematic diagram of ?CT(1-456), showing the amino acid residues in the hinge region 
involved in type I collagenolytic activity of the enzyme. The amino acids in red signify 
the amino acids individually mutated to Ala.  
 
 
Table 5-2. Proteolytic activity of the Ala mutants  
 
Enzyme 
?M-1 
 
Kcat/Km 
(McaPLGLDpaAR) 
mM
-1
S
-1
 
Specific Activity 
for Gelatin 
?g/h/nmol 
Kcat 
Type I 
collagen 
Km 
Type I 
collagen 
Kcat/Km 
Type I 
collagen 
   h
-1
 ?M-1 h-1 ?M-1 
MMP-1 14.17 ± 0.5 272 ± 9 146 5.36 27.23 
?CT(1-456) 128.9 ± 14.1 58,959  ± 359 ND ND ND 
R445A 328.1 ± 11.9 71,154 ± 174 ND ND ND 
E447A 85.95 ± 1.5 10,239 ± 130 0.418 0.157 2.66 
E449A 275.37 ± 16.8 149,680± 19,758 ND ND ND 
R451A 135.1 ± 10.26 248,706± 13,896 0.641 0.236 2.71 
ND=Not Determined 
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Figure 5-5. Gelatin- gel zymography of purified site directed mutant enzymes.  
 
Lanes 1, 3, 5 and 7 correspond to the latent forms and lanes 2, 4, 6 and 8 correspond to 
the active forms of ?CT(1-456) mutant enzymes R445A, E447A, E449A, and R451A , 
respectively.  
 
 
 The catalytic efficiencies of all of the mutant enzymes toward the peptide 
substrate Mca-PLGL(Dpa)AR-NH2 and gelatin were then determined at 23 ˚C and 37 ˚C, 
respectively.   As shown in Table 5-2, all of the Ala substitutions changed catalytic 
efficiency and specific activity of the ?CT(1-456)   enzyme for peptide substrate and 
gelatin, respectively. While, R451A substitution did not have a significant effect on 
Kcat/Km value of the ?CT(1-456 ) for the synthetic substrate , the catalytic efficiency of 
R445A and E449A for the substrate were found to be 2.6 and 2.3 times higher than that 
of ?CT(1-456), respectively. The observed differences between catalytic efficiency of 
?CT(1-456) and the Ala mutant enzymes for synthetic substrate could be due to higher 
catalytic activity (Kcat) and/or higher affinity of the mutant enzymes for the synthetic 
substrate. The E447A mutant had 1.5 times lower Kcat/Km value for the synthetic 
substrate than ?CT(1-456).   
 
 All of the alanine mutations also changed specific activity of ?CT(1-456) enzyme 
for gelatin substrate.  While the specific activities of R445A, E449A, and R451A mutants 
for gelatin substrate were 1.2, 2.5, and 4.2-fold higher than that of ?CT(1-456), 
respectively, introduction of Ala mutation at position 447 in ?CT(1-456 ) reduced 
gelatinolytic activity of the enzyme by 5.7-fold (Table 5-2).  These data suggest that 
amino acid residues at positions 447, 449, and 451 are involved in general proteolytic 
activity of MMP-9. 
 
 The effect of Ala mutations in type I collagenolytic activity of  ?CT(1-456)  was 
assessed using soluble type I collagen as a substrate. As shown in Table 5-2, substitution 
of Glu
447
 and Arg
451
 with Ala endowed ?CT(1-456) with type I collagenolytic activity.   
E447A and R451A (Table 5-2) were able to cleave type I collagen less efficiently than 
?444-502 mutant enzyme (3.71 h-1?M-1; Table 5-1).  The Kcat/Km of E447A and R451A 
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mutants were 2.66 and 2.71 h
-1 ?M-1, respectively (Table 5-2). These data indicate that 
the presence of Glu
447 
and Arg
451
 residues in MMP-9 hinders the enzymes from cleaving 
type I collagen. We have previously shown that presence of Glu
415
 in the active site of 
MMP-9 also prevents the enzyme from using type I collagen as a substrate 
[105].  This was based on the observation that substituting Glu
415
 in the active site of 
MMP-9 with Gly, an amino acid counter part in MMP-1, provided the enzyme with type 
I collagenolytic activity [105]. These data together suggests that interaction between the 
side chain of Glu
447
 and/or Arg
451 
with Glu
415
 make the active site of MMP-9 rigid and 
capable of accommodating specific substrates, i.e. gelatin and type V collagen.  Removal 
of the side chain of either of these amino acid residues or a complete deletion of the hinge 
region as in ?444-502 and ?CT(1-443) mutant enzymes makes the structure of the active 
site more flexible and capable of cleaving both types I and V collagen.   
 
 
Interaction Between Glu
415
 and Glu
447
 and/or Arg
451
 Dictates Substrate Specificity 
of MMP-9 
 
 To test the above hypothesis we introduced Glu
415
 to Gly mutation into ?CT(1-456) 
and E447A/?CT(1-456) enzymes (Figure 5-6) and studied the effect of mutations on type I 
collagenolytic activity of the enzymes.  If interaction between the side chains of Glu
415
 
and Glu
447 
dictates substrate specificity of MMP-9, then removal of the side chain 
of either amino acids from ?CT(1-456)  should result in an enzyme capable of cleaving type 
I collagen in addition to gelatin and synthetic substrate. Moreover, introduction of E415G 
mutation in E447A/?CT(1-456) should, in principal,  increase the activity of the enzyme 
toward type I collagen.   
 
 As shown in Figure 5-6 and Table 5-3, the latent E415G/?CT(1-456) (E415G) and 
E415G/E447A/?CT(1-456) (DM) are 47 kDa proteins that after activation by APMA are 
 
 
     
 
 
Figure 5-6. Schematic diagram and gelatinolytic activities of E415G and DM.  
 
The figure to the left is schematic diagrams of ?CT(1-456) showing the position of Glu415 
and Glu
447
 in the protein molecule. To the right is a gelatin gel zymography depicting 
molecular weights of latent (lanes 1 and 3) and active (lanes 2 and 4) forms of 
E415G/?CT(1-456) and E415G/E447A/?CT(1-456) (DM) mutant enzymes, respectively.  
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Table 5-3. E415G and DM proteolytic activity. 
 
Enzyme 
?M-1 
Kcat/Km 
(McaPLGLDpaAR) 
mM
-1
S
-1
 
Specific 
Activity for 
Gelatin 
Kcat 
Type I 
collagen 
Km 
Type I 
collagen 
Kcat/Km 
Type I 
collagen 
  ?g/h/nmol h-1 ?M-1 h-1 ?M-1 
MMP-1 14.17 ± 0.5 272 ± 9 146 5.36 27.23 
?CT(1-456) 128.9 ± 14.1 58,959  ± 359 ND ND ND 
E415G 130.63 ± 0.53 56,779 ± 2,956 8.041 2.3 3.5 
DM 29.52 ± 0.6 39,864± 984 11.89 1.94 6.1 
ND=Not Determined  
 
 
converted to 37 kDa proteins capable of cleaving gelatin and using 
Mca-PLGL(Dpa)AR-NH2  as a substrate. The catalytic efficiency and specific activity of 
E415G for the synthetic substrate and gelatin were equal to those of ?CT(1-456), 
respectively (Table 5-3). Contrary to E415G, the catalytic efficiency of DM mutant 
enzyme for the synthetic substrate and its specific activity for gelatin were 4.4 and 
1.4-fold lower than those of ?CT(1-456)  (Table 5-3). This data confirms the previous 
observation that amino acid residue at position 447 is involved in general proteolytic 
activity of MMP-9. 
 
 The catalytic efficiency (Kcat/Km) of E415G and DM enzymes for type I 
collagen was determined at 27ºC (Table 5-3). We found that similar to previously 
described Gel.B/E415G mutant [105], mutation of Glu
415
 to Gly in ?CT(1-456) confers the 
enzyme with type I collagenolytic activity at an efficiency of 3.5 h
-1 ?M-1 (Table 5-3). 
The double mutant had a catalytic efficiency of 6.1 h
-1 ?M-1, which is 1.7- and 2.3-fold 
higher compared to individual E415G and E447A mutants, respectively (Table 5-2) and 
is equal to the efficiency of single mutants combined. This additive effect of double 
mutations on the rate of cleavage of type I collagen by ?CT(1-456) proves our hypothesis 
that the interaction between Glu
415
 and Glu
447
 is the major determinant in collagen 
substrate specificity. The interaction(s) between the side chains of Glu
447
 and Glu
415
 
makes the active site rigid, preventing the active site from accommodating type I collagen  
molecule. Breaking this interaction by either replacing, Glu
447
 or Arg
451
 to Ala makes the 
active site flexible and capable of cleaving type I collagen. 
 
 
DISCUSSION 
 
 In this report we demonstrate, for the first time, that the ability of 68 kDa MMP-9 
to cleave type I collagen comes from its active site ability to adopt a conformation that 
mediates collagen binding and catalysis and this process is dependent on the lack of 
interaction between a Glu residue at position 415 located in the AS region of the enzyme 
and Glu
477
 residue located in the hinge region. The removal of amino acid side chain at 
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positions 415 and/or 447 provides flexibility necessary for the enzyme active site to 
change conformation upon binding collagen, leading to catalysis. This is based on the 
observation that only MMP-9 mutants lacking Glu
415
 (as in E415G), Glu
447
 (as in E447A, 
?CT(1-443), and ?444-502 mutants), or their combination (as in E447A/E415G/?CT(1-456)) 
were able to use type I collagen as a substrate. The carboxyl terminal deletion mutant 
(?CT(1-456)) and full length MMP-9 although had high activity toward the peptide 
substrate and gelatin, were not able to cleave type I collagen. ?CT(1-456) was by all 
indications stable, properly folded, and able to be processed by APMA to a 37 kDa active 
species.   An amino acid sequence alignment revealed that the amino acid residues 
444-456 (
444
PRPEPEPRPPTTT
456
) is responsible for the observed difference in the type I 
collagenolytic activity of ?CT(1-456) and ?CT(1-443) mutant enzymes (Figure 5-2 and 5-4).  
 
 We have previously demonstrated that MMP-9 mutant (Gel.B/E415G), in which 
Glu
415
 located in its active site is substituted by Gly, its corresponding residue in all type 
I collagen cleaving MMPs, is able to cleave native triple helical type I collagen [105].  
These data together suggested that the interaction between Glu
415
 and an amino acid 
residue(s) in the sequence 
444
PRPEPEPRPPTTT
456 
make the active site
 
of MMP-9
 
rigid, 
preventing the enzyme from binding to and cleaving type I collagen.   
 
 This was confirmed by the observation that the replacement of Glu
447
 and Arg
451
 
in ?CT(1-456) with Ala (E447A and R451A) endowed the enzyme with type I 
collagenolytic activity (Table 5-2). These mutants retained peptide substrate and 
gelatinolytic activity, indicating that the general proteolytic activity of ?CT(1-456) was not 
compromised by these substitutions. The effect of E447A and R451A mutation on kinetic 
parameters of ?CT(1-456) for type I collagen was similar to the replacement of Glu415 with 
Gly in ?CT(1-456) (Table 5-3) and removal of the entire hinge region of MMP-9 
(?444-502;  Table 5-1). As shown in the diagram below (Figure 5-7), presence of the 13 
amino acids in full-length MMP-9 and ?CT(1-456) makes the AS of these enzymes rigid 
and blocks type I collagen from entering the AS. Further processing of 82 kDa by 
COOH-terminal truncation, to 68 kDa enzyme and deletion of the remaining hinge region 
in ?CT(1-443) removed the Glu415 and Glu447 interaction and made the AS less rigid. This 
allowed type I collagen to enter the AS of ?CT(1-443) and be cleaved with a Kcat/Km of 
1.8 h
-1 ?M-1 (Figure 5-7; bottom left). Substitution of Glu415 with Gly (Figure 5-7; top 
right), Glu
447
 (Figure 5-7; bottom right) or Arg
451
 with Ala also affected the interaction of 
the hinge region with AS Glu
415
 by breaking the side chain ionic interactions. This made 
the active site less rigid and capable of cleaving type I collagen with a Kcat/Km of 3.5, 
2.66 and 2.71 h
-1 ?M-1, respectively. These data indicated that the interaction of Glu415 
and Glu
477 
in MMP-9 dictates substrate specificity of the enzyme.  
 
This was substantiated by substituting the Glu
415
 residue with Gly and Glu
477
 with 
Ala in ?CT(1-456). The catalytic activity (Kcat) of the double mutant 
E415G/E477A/?CT(1-456)  toward type I collagen  was 1.5 and 28.4 folds higher than that 
of E415G and E477A mutants, respectively (Table 5-2 and 5-3).  The affinity of the 
double mutant for type I collagen (Km), however, was similar to that for E415G mutant. 
Generation of the E415G/E447A/?CT(1-456) (DM) lead to an additive effect on type I 
collagen catalytic efficiency. The Kcat/Km of 6.1 h
-1 ?M-1 was approximately 2 times 
60 
 
 
 
   
Figure 5-7. Schematic diagram of MMP-9 mutants with type I collagenolytic 
activity.  
 
This diagram shows full length MMP-9 without any mutations (upper left) and the 
rigidity of the AS caused by the interaction between Glu
415
 and Glu
447
, which inhibits 
type I collagen (green ball) from entering the AS. When Glu
415
 is mutated to Gly (upper 
right), the hinge region is completely deleted (lower left), or Glu
447
 is mutated to Ala 
(lower right) the interaction between Glu
415
 and Glu
447
 is broken and the enzyme gains 
type I activity. 
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higher compared to E415G, E447A, and R451A single mutations in ?CT(1-456).  
 
 According to the X-ray crystal structures of MMP-9 catalytic domain [105] and 
full length MMP-1 [110], Glu
415 
is located in a turn at the bottom of the AS where the 
polypeptide chain turns back towards the center of the enzyme and Glu
447
 and Arg
451
 are 
located at the beginning of the hinge region (Figure 5-7).  Considering that Glu
415
 is not 
positioned along the enzyme/substrate interface, it is unlikely that it or a substituting 
residue would directly interact with the collagen substrate. The significance of this 
residue in type I collagenolysis is probably related to its direct/indirect interaction with 
Glu
447
/Arg
451
 affecting the conformation and flexibility of the AS of the enzyme.  Thus, it 
is conceivable that any substitution at these positions have a general effect on the 
mobility of the AS. The observation that the ?CT(1-443), E415G, E477A R451A and 
?444-502 mutant enzymes are capable of cleaving type I collagen supports this notion 
and suggests that the flexibility provided by the lack of Glu
415
-Glu
447
 interaction is 
essential for type I collagenolytic activity. Consistent with this hypothesis is also the fact 
that full length MMP-9 and ?CT(1-456) mutant enzymes cannot cleave native type I 
collagen substrate (Table 5-1). Thus, it is reasonable to conclude that the interaction of 
Glu
415 
with the hinge region makes the active site rigid, preventing MMP-9 from cleaving 
type I collagen. Disruption of this interaction, on the other hand, provides the flexibility 
necessary for enzyme active site to change conformation and be able to bind and cleave 
collagen substrate.   
 
 These data indicate that therapeutic studies which target only MMP-1 may not be 
very effective due to the cleavage of type I collagen by the fully processed MMP-9. Thus, 
this novel role identified for the type V collagen-like hinge region of MMP-9 in cleavage 
of type I collagen aids in understanding the relationship between the structure and 
function of MMPs and the involvement of different exocites in the substrate specificity. 
This can lead to discovery of novel and targeted therapeutic agents.  
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CHAPTER 6.    SUMMARY 
 
  
 Increasing evidence suggests that MMPs contribute to the formation of a 
microenvironment that promotes tumor growth during early stages of tumorigenesis. 
MMP-9 is one of the most important factors for metastatic behavior of tumor cells [23, 
54, 74]. MMP-9 expression has been shown to be upregulated in breast tumors isolated 
from cancer patients [73]. MMP-9 degrades type IV collagen, one of the most abundant 
collagens in the ECM [11, 75] and is involved in cell proliferation, angiogenesis, and 
apoptosis [9, 10, 30]. Our observation that AM9D specifically decreased MMP-9 mRNA 
and protein production (Figure 1-3b and c) and reduced invasive behavior of human 
MDA-MB-231 cells (Figure 1-3d) suggested that AM9D has potential as an anti 
tumorigenic/metastatic agent.  
  
 MMTV-PyMT transgenic mice were used to test the effect of AM9D on tumor 
growth in vivo. This model was chosen because of its similarity to human breast cancer 
and its metastatic potential. AM9D treatment of 10 ?g and 25 ?g/tumor/week for a total 
of four weeks showed a 39.5 and 50% reduction in final tumor load. 
Immunohistochemical analysis of tumor tissues showed that AM9D treatment reduced 
MMP-9 production in tumor cells by 66% compared to control DNAzyme treatment. In 
addition, AM9D treatment decreased vasculature and induced apoptosis in mammary 
tumors as demonstrated by CD31 and Caspase-3 immunostaining, respectively. These 
results showed promise as to the use of AM9D to treat tumor growth in vivo. However, 
there were several limitations in this study. First, the tumors of the MMTV-PyMT model 
developed at different time points and only the earlier developed tumors being treated 
with AM9D or control DNAzyme. This led to termination of treatment after 4 injections. 
Second, due to the development of the large size mammary tumors during the course of 
the treatment, the mice were sacrificed prematurely, inhibiting our ability to fully assess 
the effect of AM9D on spontaneous lung metastasis. Thus, experimental metastasis was 
utilized to determine the effect of AM9D on metastasis.  
 
 To utilize AM9D as a therapeutic treatment in experimental metastasis, AM9D 
needed to first be evaluated for its distribution, clearance and safety in normal and 
MMTV-PyMT mice. Healthy FVB and MMTV-PyMT mice were injected with naked 
[
35
S]-AM9D (10 mg/kg) in PBS via tail vein. [
35
S]-DNAzyme was distributed to all 
major organs in mice, including liver, kidney, lung, spleen, heart, pancreas, intestines, 
stomach, and brain (Figure 3-2). In normal mice the order of percentage accumulation 
was: blood>liver>kidney>lung>spleen>heart. Studies revealed 1.8%, 1.1% and 0.4% of 
total DNAzyme injected was delivered to liver, kidney, and lung, respectively (Table 
3-1). In MMTV-PyMT mice bearing small to large mammary tumors, the order of 
percentages of [
35
S]-DNAzyme accumulation in different organs was  
mammary tumor>liver?blood>kidney>spleen>lung>heart. In these mice, 4.1% of the 
total injected DNAzyme was accumulated in the mammary tumors in 2 h (Table 3-3) and 
the amount of DNAzyme accumulated in mammary tumors was proportional to the total 
weight of tumor burden (Figure 3-4). Interestingly, the accumulated DNAzyme in the 
mammary tumor is initially cleared at a slower rate compared to the other organs. The 
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percentages of total DNAzyme accumulated in various organs in MMTV-PyMT mice 
were similar to normal mice (Table 3-1 and 3-3). In normal and MMTV-PyMT mice the 
majority of the DNAzyme was cleared from these organs within the first 24 h. Thirty-one 
percent of the delivered dosage of [
35
S]-DNAzyme was cleared from the system of 
normal mice via feces and urine over a period of 72 h (Figure 3-1b). The safety of 
DNAzyme was tested by a single injection or AM9D or control DNAzyme in various 
concentrations (10 mg/kg, 32 mg/kg, and 75 mg/kg of body weight) and 100 ?l PBS into 
normal FVB mice. Systemic distribution and safety/toxicity studies revealed that the 
naked AM9D is non-toxic when systemically administered, and has favorable 
pharmacological properties with respect to intravenous administration and tissue 
distribution. Most importantly, mammary tumors can take up the naked DNAzyme.  The 
amount of DNAzyme accumulates in the mammary gland is higher and its rate of 
clearance is slower than any other organs tested. Taken together, these data show the 
potential of DNAzymes to be distributed to organs susceptible to tumors (brain, pancreas, 
stomach, etc.), taken up by tumors, and display extended half-life in tumors.  
 
 AM9D and control DNAzyme both showed evidence of a possible sequence 
related affect on metastasis when used as therapy for early stage experimental metastases. 
This may be due to AM9D and control DNAzyme containing CpG regions. CpG 
monotherapy has been shown to induce T-cell-mediated rejection of established tumors 
[91]. Assessment of long term lung tumor burden and survival suggests that AM9D 
treated mice have an advantage of progression-free survival over mice treated with 
control DNAzyme or PBS between days 32-42, however, all cohorts were eventually 
overcome by an equal volume of lung tumor burden (Figure 4-4) and there was no 
advantage of overall survival in either groups. This lack of effect maybe due to time of 
AM9D delivery, frequency of delivery, mouse strain, pro-tumorigenic effects of MMP-9 
downregulation, or a combination of these effects. These are all concerns that must be 
investigated to confirm the anti-metastatic effect of AM9D.  
 
 Finally, in this body of work we showed that MMP-9, through its cleavage of type 
I collagen, might play a more important role in tumorigenesis than once believed. We 
have demonstrated that 68 kDa truncated fully processed MMP-9 in addition to type IV 
collagen, is capable of cleaving type I collagen. Kinetic analysis of truncated MMP-9 
demonstrated that amino acid sequence 444-456 in the hinge region of MMP-9 is 
responsible for substrate specificity of the enzyme. The absence of this region in 
?CT(1-443) and ?444-502 garnered these enzymes with type I collagenolytic activity. 
Further analysis of amino acid sequence 444-456 identified the two amino acids Glu
447
 
and Arg
451
 as being directly involved in substrate recognition by the enzyme. Substitution 
of Glu
415
 with Gly and/or replacement of Glu
447
 and Arg
451
 with Ala in ?CT(1-456) made 
the enzyme capable of using type I collagen as a substrate. The catalytic efficiency of the 
double mutant (E415G/E447A/?CT(1-456)) toward type I collagen was 2-fold higher than 
either E415G or E447A mutant, indicating that interaction of Glu
415
 with Glu
447 
dictates 
substrate specificity of the enzyme. Lack of this interaction makes the active site flexible, 
allowing the enzyme to cleave both type IV and I collagen, the two most important 
components of the ECM. This observation is important because it further illuminates the 
role of MMP-9 in tumorigenesis and metastases. 
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CHAPTER 7.    AM9D: FROM PRECLINIC TO CLINIC 
 
 
AM9D FOR BREAST CANCER PATIENTS 
 
 There are several lines of evidence that suggest MMP-9 levels in serum and tissue 
could be a sensitive biomarker for tumor aggressiveness and metastasis in breast cancer 
patients [111-115]. Moses, et al. first described that the analysis of urinary MMP-9 may 
be a useful determinant for disease status in a variety of human cancers, including breast 
cancer [113]. In this study, urine specimens were obtained from patients prior to surgical 
or other therapeutic intervention and all breast cancer urine specimens were obtained 
from patients with metastatic disease. One hundred percent of these specimens were 
positive for MMP-9 compared to only 24% of normal control breast tissue [113]. 
Pellikainen, et al. evaluated the expression of MMP-9 in estrogen receptor positive 
(ER+/HER2) breast cancer patients and discovered positive stromal MMP-9 expression 
predicted decreased progression-free survival and decreased overall survival [116]. 
Furthermore, Wu, et al. measured serum and tissue levels of MMP-9 in breast cancer 
patients, benign breast disease patients, and healthy controls and correlated the levels 
with patients’ clinicopathologic characteristics [112]. Sixty-three and 77% of the breast 
cancer patients displayed high MMP-9 serum levels and tissue staining, respectively, that 
positively correlated with lymph node metastasis [112].  
 
 As described earlier (Chapter 1), breast cancer is divided into 3 subtypes: luminal 
A (ER or PR
+
/HER2
-
), luminal B (ER or PR
+
/HER2
+
), and triple negative 
(ER
-
/PR
-
/HER2
-
). Interestingly, MMP-9 serum levels were equally increased in HER2
+
 
and HER2
-
 patients, as well as, ER
+
 and ER
-
 breast cancer patients [112]. Triple negative 
breast cancer accounts for approximately 15% of breast cancer cases and is marked with 
high relapse rates, metastasis, and early death [117]. In a comparison of breast cancer 
patients with triple-negative or HER2 overexpression, the triple-negative patients 
experienced more lymph node metastasis compared to those with overexpressed HER2 
[118]. MMP-9 expression was positively correlated with lymph node metastasis in breast 
cancer patients [112]. Additionally, the 5 year disease-free survival in patients with 
triple-negative was much shorter than HER2-expressing patients [118]. The lack of 
standard therapy and poor prognosis are causes of the high mortality [117]. Targeting 
MMP-9 that has been shown to be expressed in hormone positive and negative breast 
cancer patients, could play an important role in tumor treatment and reduce metastasis to 
lymph nodes and other metastatic sites of breast cancer patients. We have shown the 
distribution of MMP-9 DNAzyme (AM9D) to all major organs, including lung, brain and 
liver (Chapter 3, Figure 3-2). To this end, AM9D will be a useful therapeutic treatment 
for hormone positive and negative breast cancer patients at the early stages of tumor 
growth and metastasis.  
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AM9D AS AN ADJUVANT TO SURGERY 
 
 MMPs play a role in the normal physiology and pathology of wound healing. 
When tissue suffers injury cell proliferation increases, inflammatory cells infiltrate the 
wounded area and release MMPs, including MMP-9, while the tissue regenerates [119]. 
A first line treatment for breast tumor is surgical excision. Zhao, et al., demonstrated that 
surgical excision of an implanted MDA-MB-245 mammary tumor in mice led to 
increased serum expression of MMP-9 on days 1, 3, 19, 26, 33, and 40 after surgical site 
wounding compared to non-surgical tumor bearing control cohorts [115]. This increased 
MMP-9 expression was positively correlated with the increased tumor volume in the 
surgery group between weeks 4-6 compared to the control group. Furthermore, elevated 
host serum MMP-9 levels, as a result of surgery wound, was positively correlated to 
metastatic lung tumor burden at the study endpoint [115]. To my knowledge, no studies 
have been performed on breast cancer patients to determine the levels of MMP-9 serum 
expression post surgical incision. However, if MMP-9 serum expressions in patients 
mimic those of preclinical studies, AM9D would play an important therapeutic role as an 
adjuvant to breast tumor surgery to abate tumor metastasis and surgery-stimulated growth 
at the site of excision.  
 
 
FUTURE AM9D PRECLINICAL STUDIES 
 
 MMPs are considered promising targets for breast cancer therapy because of their 
major involvement in malignant pathologies and metastasis to distant organs [120]. The 
preclinical studies outlined in this body of work further display the therapeutic potential 
of downregulating MMP-9 expression by an MMP-9 specific catalytic DNA molecule. 
While we show the efficacy of AM9D on reducing tumor growth (Chapter 2), its 
efficiency on inhibition of metastasis needs to be further explored. We displayed that a 
majority of DNAzyme is cleared from major organs, including lung, in the first 24 h 
(Chapter 3, Figures 3-1 and 3-3). The chronic cytotoxicity experiments for DNAzyme 
were performed with weekly injections of DNAzyme for 9 weeks (Chapter 4, Figure 
4-5). To further explore AM9D efficacy on the treatment of metastasis, a therapeutically 
efficient regimen must be determined. To accomplish this goal DNAzyme injections 
could be increased from weekly to daily injections over a period of 3 weeks for survival 
analysis upon early stage metastasis and until mice are overcome by tumor burden. 
Performing daily injections of 75 mg/kg AM9D for a period of 3 weeks would expose 
animals to a total of 1,575 mg/kg DNAzyme, which would require re-evaluation of mice 
for cytotoxicity. This would be a 7-fold increase from the original 225 mg/kg injected in 
previous experiments and should escalate DNAzyme accumulation in major organs.  
 
 If multiple injections prove to be too cumbersome, DNAzyme can be packaged 
into nanoparticles as an alternate delivery approach. Designing nanoparticles has the 
added effect of targeting two metastatic sites, such as lung and liver, simultaneously 
[121]. Targeted delivery is a promising method for the development of efficient and safe 
therapeutic molecules for oncology [122]. Rapid vasculature development in tumor 
results in larger than normal pore size within vessel walls, which allows nanoparticles to 
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more easily extravasate into tumor tissue than normal tissue [123]. Tumor tissues also 
contain a deficiently developed lymphatic system that limits drainage of nanoparticles. 
Therefore, nanoparticles can improve the accumulation of DNAzyme within the tumor 
through their enhanced permeability and retention capabilities [123]. Similar to our 
observations of DNAzyme clearance (Chapter 3), Bellocq, et al. showed the majority of 
systemically administered DNAzyme cleared from organs after 24 h in mice. However, 
they found that injecting DNAzyme packaged with transferrin-modified polyplexes 
nanoparticle resulted in slower clearance of DNAzyme compared to DNAzyme packaged 
with non-modified polyplexes [121]. Transferrin receptor (Tf-R) is often upregulated in 
rapidly growing cells; furthermore, lung and liver both have high Tf-R expression [121]. 
Packaging our AM9D with transferrin-modified polyplexes would require additional 
functional and pharmacokinetic studies; however, this could decrease non-specific 
distribution throughout the body, decrease the observed rapid excretion, and increase 
accumulation thereby eliminating the need for daily injections of AM9D.   
 
 In lieu of the emerging organ toxicities and side effects of broad spectrum 
inhibitors, including tyrosine kinase inhibitors [124], we cannot ignore the possibility of 
AM9D side effects surfacing. While we showed no evidence of organ toxicity in mice 
injected with DNAzyme (Chapter 3), we negated to observe normal mammary tissue for 
the presence of toxicity in these studies. MMP-9 has been shown to be present in normal 
breast tissue [125]. To my knowledge, there are no studies outlining a clear role of 
MMP-9 in normal breast tissue. Therefore, the down regulation of MMP-9 in normal 
breast tissue by AM9D may lead to potential side effects. Any possible toxicities may be 
found through the investigation of MMP-9 in normal breast tissue in the absence and 
presence of AM9D.  
 
 AM9D opens the door to the development of effective anti-MMP therapies. 
AM9D could be used as a therapy for hormone positive and negative breast cancer 
patients as an adjuvant to surgery and in combination with other chemotherapeutic 
modalities. Overall, AM9D shows promise as a therapeutic modality for breast cancer 
treatment and warrants further investigation.  
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APPENDIX.  DEVELOPMENT OF AM9D MATERIALS AND METHODS 
 
 
DNAZYME 
 
 Several DNAzyme molecules were synthesized by Integrated DNA Technology 
(Coralville, IA). All the DNAzymes consisted of nine oligonucleotides on each arms 
complementary to different regions of MMP-9 mRNA flanking the nucleotide 10-23 
catalytic core [49, 126].  Sequences of DNAzymes targeting mRNA of MMP-9 were,  
AM9D-1: 5’-AGCCCAGCAggctagctacaacgaCAGGAGCAC-3’; 
AM9D-2: 5’-AAGGGTGGAggctagctacaacgaTGGCGCTGT-3’;  
AM9D-3 5’-ATAGCGGTAggctagctacaacgaAGGTATTCC-3’;  
AM9D-4: 5’-CCCCAGAGAggctagctacaacgaTTCGACTCT-3’;  
AM9D-5: 5’-GTGGTGCCAggctagctacaacgaTTGAGGTCG-3’. Scrambled DNAzyme 
(CTAGTCAGCggctagctacaacgaTAAGCTGCT), where the arms flanking the 10-23 
catalytic core were composed of random sequence and sense control DNAzymes 
containing sense oligonucleotide sequences corresponding to each DNAzyme in both 
arms were used as negative controls.  Nucleotides in lower case represent the 10-23 
catalytic domain and the corresponding MMP-9 sequences are in capital. Where 
indicated, DNAzymes were fluorescently labeled at 5’ end with Oregon Green? 488 
maleimide as suggested by the manufacture (Molecular Probes, Eugene, OR). The 
labeled oligonucleotides were purified with the MERmaid Kit (BIO 101, La Jolla, CA). 
 
 
IN VITRO TRANSCRIPTION AND CLEAVAGE ANALYSIS OF MMP-9 RNA BY 
DNAZYMES  
 
 The 764-nucleotide MMP-9 RNA transcript was prepared by in vitro 
transcription (T3 polymerase) of pBSNG4.1 [75] digested with Bsm1 restriction 
enzyme.   DNAzymes (12.5 μM) were incubated with the RNA substrate (0.48 μM) in 
50 mM Tris-HCl, pH 7.5, containing 10 mM MgCl2 at 37 ˚C for 2 h. The reactions were 
stopped with 90% formamide in TBE and the reaction products were separated on a 4% 
polyacrylamide-urea gel. The RNA products were stained with Ethidium Bromide and 
their intensities were determined using an Alpha Imager 2000 documentation and 
analysis system (Alpha Innotech Corp., San Leandro, CA). 
 
 
CELL TRANSFECTION  
 
The COS-7 and MDA-MB-231 cell lines were obtained from American Type 
Culture Collection (ATTC, Manassas, VA). COS-7 cells were grown in Dulbecco’s 
modified Eagles medium (DMEM), pH 7.4, containing 10% fetal bovine serum (FBS), 
100 i.u./ml penicillin, and 100 μg/ml streptomycin at 37 ˚C in a humidified atmosphere 
of 10% CO2. The COS-7 NG was generated by stably transfecting COS-7 cells with 
pcDNA3-MMP-9. Sub-confluent COS-7 NG cells (60-70%) were incubated in serum 
free medium and transiently transfected with Oregon Green? 488 maleimide labeled 
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DNAzyme (AM9D-5; 24 μg) using DOTAP transfection reagent according to the 
manufacturer’s instruction (Roche, Mannheim, Germany).  After 24 h incubation at     
37 ˚C in serum free medium, cells were collected, sorted, and the transfected cells were 
isolated for further analysis.  MDA-MB-231 human breast cancer cells (ATCC; 
Manassas, VA) were plated onto 10 cm dishes in DMEM media supplemented with 10% 
fetal bovine serum (FBS) and allowed to grow to 80-90% confluence at 37 ˚C with 5% 
CO2. The cells were then serum-starved for 4 hours prior to transient transfection with 
Oregon Green? 488-maleimide -labeled AM9D-5 or control DNAzyme (24 μg) using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After a 18 h incubation at 37 ˚C in 
serum free medium, transfected cells were sorted for the presence of Oregon Green on a 
BD Biosciences Aria cytometer and positive cells were collected for further analysis.  
 
 
ANALYSIS OF MMP-9 MRNA AND PROTEIN PRODUCTION IN AM9D 
TRANSFECTED CELLS 
  
 The amount of MMP-9 mRNA and its enzyme activity in the DNAzyme 
transfected COS-7 NG cells were measured by reverse transcription-polymerase chain 
reaction (RT-PCR) and gelatin gel zymography [75], respectively. Total RNA from the 
transfected COS-7 NG cells was isolated by Trizol reagent (Invitrogen, Carlsbad, CA) 
and reverse transcribed with random hexamer primers (Promega, Madison, WI) using 
MMLV-RT enzyme (Invitrogen, Carlsbad, CA). The amount of MMP-9 mRNA present 
in the RNA samples was quantified by PCR using specific MMP-9 primers (forward; 
5’-GCAGGAATGCGGCTCTGG-3’ and reverse primer; 
5’-CCCGTCGAAGGGATACC-3’). ?-actin mRNA was also amplified as an internal 
control, with forward; 5’-CAAGAGATGGCCACGGCGGCT-3’ and reverse; 
5’-TCCTTCTGCATCCTGTCAGCA-3’ Primers.  The PCR products were subjected to 
1% agarose gel and visualized by Ethidium Bromide staining. MMP-9 expression was 
quantified by an alpha imager 2000 documentation and analysis system (Alpha Innotech 
corporation San Leandro, CA). 
 
 
CELL INVASION ASSAY 
 
 MDA-MB-231 cells were transfected with fluorescently labeled AM9D-5 or 
control DNAzyme for 18 h in serum free DMEM medium as above. The fluorescent 
positive cells was identified by flow cytometry, isolated and seeded in ECMatrix™   
invasion chambers (Millipore, Billerica, MA).  After 24 h incubation at 37 ˚C with 5% 
CO2, the number of cells that migrated though the ECM layer and attached to the 
polycarbonate membrane was quantified spectrophotometerically at 560 nm according 
to the manufacturer’s protocol. All assays were conducted in triplicate and the values 
were averaged.  
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